A Phase 3 interventional study of Belimumab 1 mg/kg and Belimumab 10 mg/kg in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 12th largest by enrollment, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 7th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 268 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 13th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2008, is one of 10 in phase 3, and was the 7th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Belimumab 1 mg/kg IV every 28 days
Biological: Belimumab 1 mg/kg
Belimumab 10 mg/kg IV every 28 days
Biological: Belimumab 10 mg/kg
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.
Time frame: Up to Week 440
AE Rates by System Organ Class (SOC) During the Study
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / Participant Years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
Time frame: Up Week 440
SAE Rates by System Organ Class (SOC) During the Study
SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / participants Years. participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
Time frame: Up to Week 440
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Erythrocytes at the Indicated Time Points
Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Hematocrit at the Indicated Time Points
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Hemoglobin at the Indicated Time Points
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Albumin and Protein at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Creatinine Clearance at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in BUN/Creatinine at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Number of Participants With the Indicated Immunogenic Response
Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.
Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (\<0.5 nanograms per milliliter \[ng/mL\]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 392
Percentage of Participants Achieving SRI Response at Indicated Time Points
The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:\>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Observed Anti-double Stranded DNA Levels at Indicated Time Points.
Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA \>=30 International Units/milliliter \[IU/mL\]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.
Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Observed Complement C3 and C4 Levels at Indicated Time Points
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligram per deciliter (mg/dL) and C4 \<16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 440
Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligrams per decilitre (mg/dL) and C4 \<16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.
Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.
Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with \>= 50% reduction in proteinuria among participants with Baseline proteinuria \>0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Observed B-cell Levels at Indicated Time Points.
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Up to Week 432
Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points
Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change \>0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).
Time frame: Up to Week 384
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point
The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).
Time frame: Up to Week 384
Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints
The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).
Time frame: Up to Week 384
Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).
Time frame: Up to Week 384
Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (\>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).
Time frame: Up to Week 384
| Milestone | Belimumab 10 mg/kg IV |
|---|---|
| Started | 268 |
| Completed | 140 |
| Not completed | 128 |
| Withdrew: Adverse event | 25 |
| Withdrew: Lack of efficacy | 14 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Non-compliance with study drug | 6 |
| Withdrew: Physician decision | 17 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 31 |
| Withdrew: Sponsor decision to end study | 14 |
| Withdrew: Subject incarcerated | 1 |
| Withdrew: Developed withdrawal criteria- pregnancy | 4 |
| Withdrew: Subject moved out of state | 1 |
| Withdrew: Elected to exit due to site closure | 2 |
An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| AE, Any time post baseline, n=268 | 267 |
| AE, Year 0-1, n=268 | 260 |
| AE, Year 1-2, n=259 | 235 |
| AE, Year 2-3, n=244 | 206 |
| AE, Year 3-4, n=219 | 184 |
| AE, Year 4-5, n=202 | 167 |
| AE, Year 5-6, n=192 | 145 |
| AE, Year 6-7, n=130 | 87 |
| AE, Year 7 plus, n=65 | 31 |
| SAE, Any time post baseline, n=268 | 112 |
| SAE, Year 0-1, n=268 | 33 |
| SAE, Year 1-2, n=259 | 30 |
| SAE, Year 2-3, n=244 | 25 |
| SAE, Year 3-4, n=219 | 22 |
| SAE, Year 4-5, n=202 | 24 |
| SAE, Year 5-6, n=192 | 16 |
| SAE, Year 6-7, n=130 | 13 |
| SAE, Year 7 plus, n=65 | 3 |
AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / Participant Years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
| Adverse events/100 participant-years | Belimumab 10 mg/kg IV |
|---|---|
| Infections and infestations | 134.4 |
| Musculoskeletal and connective tissue disorders | 75.5 |
| Gastrointestinal disorders | 53.6 |
| Injury, poisoning and procedural complications | 32.3 |
| Skin and subcutaneous tissue disorders | 30 |
| Nervous system disorders | 29.7 |
| Respiratory, thoracic and mediastinal disorders | 28.5 |
| General disorders and administration sitecondition | 27.9 |
| Psychiatric disorders | 12.4 |
| Metabolism and nutrition disorders | 10.1 |
| Vascular disorders | 9.1 |
| Investigations | 9.1 |
| Eye disorders | 8.2 |
| Reproductive system and breast disorders | 6.7 |
| Cardiac disorders | 6.4 |
| Immune system disorders | 6 |
| Renal and urinary disorders | 5.3 |
| Neoplasms benign, malignant and unspecified | 5 |
| Blood and lymphatic system disorders | 4.4 |
| Ear and labyrinth disorders | 3.8 |
| Hepatobiliary disorders | 2.3 |
| Endocrine disorders | 1.8 |
| Social circumstances | 0.8 |
| Congenital, familial and genetic disorders | 0.5 |
| Pregnancy, puerperium and perinatal conditions | 0.1 |
SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100\* Number of Events / participants Years. participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.
| Adverse events/100 participant-years | Belimumab 10 mg/kg IV |
|---|---|
| Infections and infestations | 4 |
| Gastrointestinal disorders | 2.2 |
| Musculoskeletal and connective tissue disorders | 2 |
| General disorders and administration sitecondition | 1.7 |
| Nervous system disorders | 1.4 |
| Injury, poisoning and procedural complications | 1.4 |
| Vascular disorders | 1 |
| Neoplasms benign, malignant and unspecified | 1 |
| Respiratory, thoracic and mediastinal disorders | 0.7 |
| Cardiac disorders | 0.6 |
| Metabolism and nutrition disorders | 0.6 |
| Psychiatric disorders | 0.5 |
| Renal and urinary disorders | 0.5 |
| Hepatobiliary disorders | 0.4 |
| Blood and lymphatic system disorders | 0.3 |
| Reproductive system and breast disorders | 0.3 |
| Immune system disorders | 0.1 |
| Investigations | 0.1 |
| Skin and subcutaneous tissue disorders | 0.1 |
| Congenital, familial and genetic disorders | 0.1 |
| Endocrine disorders | 0.1 |
| Eye disorders | 0.1 |
| Pregnancy, puerperium and perinatal conditions | 0.1 |
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Seconds | Belimumab 10 mg/kg IV |
|---|---|
| APTT, Year 1, Week 4, n= 82 | 1.3 ± 4.46 |
| APTT, Year 1, Week 12, n= 79 | 1 ± 4.56 |
| APTT, Year 1, Week 24, n= 243 | 0.7 ± 4.81 |
| APTT, Year 1, Week 36, n= 71 | 1.4 ± 4.83 |
| APTT, Year 1, Week 48, n= 246 | 1.7 ± 5.37 |
| APTT, Year 2, Week 24, n= 231 | 2.7 ± 5.88 |
| APTT, Year 2, Week 48, n= 220 | 3.9 ± 5.39 |
| APTT, Year 3, Week 24, n= 206 | 4.5 ± 4.92 |
| APTT, Year 3, Week 48, n= 202 | 4 ± 5.34 |
| APTT, Year 4, Week 24, n= 201 | 4.2 ± 6.51 |
| APTT, Year 4, Week 48, n= 185 | 4.7 ± 8.19 |
| APTT, Year 5, Week 24, n= 174 | 4.7 ± 7.03 |
| APTT, Year 5, Week 48, n= 171 | 3.6 ± 5.46 |
| APTT, Year 6, Week 24, n= 160 | 4.3 ± 6.37 |
| APTT, Year 6, Week 48, n= 126 | 4.8 ± 7.71 |
| APTT, Year 7, Week 24, n= 118 | 4.4 ± 4.77 |
| APTT, Year 7, Week 48, n= 92 | 5 ± 9.55 |
| APTT, Year 8, Week 24, n= 59 | 4.7 ± 5.02 |
| APTT, Year 8, Week 48, n= 28 | 4.7 ± 5.51 |
| APTT, Year 9, Week 24, n= 2 | 8.5 ± 13.44 |
| APTT, Exit, n= 230 | 3.1 ± 6.72 |
| APTT, 8 Week, Follow-Up, n= 104 | 3.3 ± 8.58 |
| PT, Year 1, Week 4, n= 82 | -0.05 ± 1.463 |
| PT, Year 1, Week 12, n= 79 | -0.66 ± 3.502 |
| PT, Year 1, Week 24, n= 244 | -0.04 ± 3.239 |
| PT, Year 1, Week 36, n= 71 | -0.42 ± 3.943 |
| PT, Year 1, Week 48, n= 246 | 0.2 ± 4.493 |
| PT, Year 2, Week 24, n= 233 | 0.52 ± 5.059 |
| PT, Year 2, Week 48, n= 221 | 0.24 ± 2.693 |
| PT, Year 3, Week 24, n= 206 | 0.26 ± 2.983 |
| PT, Year 3, Week 48, n= 202 | 0.34 ± 3.77 |
| PT, Year 4, Week 24, n= 201 | 0.39 ± 3.047 |
| PT, Year 4, Week 48, n= 186 | 1.96 ± 14.36 |
| PT, Year 5, Week 24, n= 174 | 0.6 ± 3.56 |
| PT, Year 5, Week 48, n= 172 | 0.5 ± 5.488 |
| PT, Year 6, Week 24, n= 160 | 0.39 ± 3.333 |
| PT, Year 6, Week 48, n= 126 | 0.55 ± 3.473 |
| PT, Year 7, Week 24, n= 118 | 0.72 ± 3.23 |
| PT, Year 7, Week 48, n= 92 | 0.68 ± 5.149 |
| PT, Year 8, Week 24, n= 58 | 0.5 ± 2.401 |
| PT, Year 8, Week 48, n= 28 | 1.85 ± 4.759 |
| PT, Year 9, Week 24, n= 2 | 1.45 ± 2.758 |
| PT, Exit, n= 229 | 0.57 ± 3.972 |
| PT, 8 Week, Follow-Up, n= 103 | 0.33 ± 2.202 |
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Billion cells per liter | Belimumab 10 mg/kg IV |
|---|---|
| Basophils, Year 1, Week 4, n= 257 | 0.001 ± 0.0157 |
| Basophils, Year 1, Week 12, n= 249 | 0.002 ± 0.0173 |
| Basophils, Year 1, Week 24, n= 249 | 0.003 ± 0.0175 |
| Basophils, Year 1, Week 36, n= 240 | 0.003 ± 0.0172 |
| Basophils, Year 1, Week 48, n= 254 | 0.001 ± 0.016 |
| Basophils, Year 2, Week 24, n= 250 | 0.002 ± 0.0159 |
| Basophils, Year 2, Week 48, n= 233 | 0.001 ± 0.0157 |
| Basophils, Year 3, Week 24, n= 219 | 0.004 ± 0.0156 |
| Basophils, Year 3, Week 48, n= 211 | 0.004 ± 0.0179 |
| Basophils, Year 4, Week 24, n= 210 | 0.004 ± 0.0157 |
| Basophils, Year 4, Week 48, n= 194 | 0.002 ± 0.0159 |
| Basophils, Year 5, Week 24, n= 188 | 0.003 ± 0.0168 |
| Basophils, Year 5, Week 48, n= 184 | 0.005 ± 0.0226 |
| Basophils, Year 6, Week 24, n= 176 | 0.003 ± 0.0149 |
| Basophils, Year 6, Week 48, n= 132 | 0.003 ± 0.0178 |
| Basophils, Year 7, Week 24, n= 122 | 0.005 ± 0.0189 |
| Basophils, Year 7, Week 48, n= 96 | 0.009 ± 0.0188 |
| Basophils, Year 8, Week 24, n= 60 | 0.002 ± 0.0155 |
| Basophils, Year 8, Week 48, n= 29 | 0.002 ± 0.0147 |
| Basophils, Year 9, Week 24, n= 2 | 0.02 ± 0.0141 |
| Basophils, Exit, n= 233 | 0.005 ± 0.0183 |
| Basophils, 8 Week, Follow-Up, n= 106 | 0.004 ± 0.0186 |
| Eosinophils, Year 1, Week 4, n= 257 | -0.001 ± 0.0893 |
| Eosinophils, Year 1, Week 12, n= 249 | 0.005 ± 0.1089 |
| Eosinophils, Year 1, Week 24, n= 249 | 0.008 ± 0.1281 |
| Eosinophils, Year 1, Week 36, n= 240 | 0.004 ± 0.1279 |
| Eosinophils, Year 1, Week 48, n= 254 | 0.007 ± 0.1216 |
| Eosinophils, Year 2, Week 24, n= 250 | 0.006 ± 0.1228 |
| Eosinophils, Year 2, Week 48, n= 233 | -0.009 ± 0.1234 |
| Eosinophils, Year 3, Week 24, n= 219 | -0.002 ± 0.1303 |
| Eosinophils, Year 3, Week 48, n= 211 | -0.023 ± 0.1276 |
| Eosinophils, Year 4, Week 24, n= 210 | -0.034 ± 0.125 |
| Eosinophils, Year 4, Week 48, n= 194 | -0.032 ± 0.1407 |
| Eosinophils, Year 5, Week 24, n= 188 | -0.038 ± 0.1281 |
| Eosinophils, Year 5, Week 48, n= 184 | -0.019 ± 0.1547 |
| Eosinophils, Year 6, Week 24, n= 176 | -0.027 ± 0.1169 |
| Eosinophils, Year 6, Week 48, n= 132 | -0.038 ± 0.1227 |
| Eosinophils, Year 7, Week 24, n= 122 | -0.017 ± 0.1269 |
| Eosinophils, Year 7, Week 48, n= 96 | -0.026 ± 0.1401 |
| Eosinophils, Year 8, Week 24, n= 60 | -0.031 ± 0.1425 |
| Eosinophils, Year 8, Week 48, n= 29 | -0.032 ± 0.1121 |
| Eosinophils, Year 9, Week 24, n= 2 | -0.08 ± 0.0141 |
| Eosinophils, Exit, n= 233 | -0.026 ± 0.1295 |
| Eosinophils, 8 Week, Follow-Up, n= 106 | -0.022 ± 0.1401 |
| Leukocytes, Year 1, Week 4, n= 257 | 0.08 ± 1.642 |
| Leukocytes, Year 1, Week 12, n= 249 | 0.18 ± 1.856 |
| Leukocytes, Year 1, Week 24, n= 249 | -0.02 ± 1.884 |
| Leukocytes, Year 1, Week 36, n= 240 | 0.04 ± 2.092 |
| Leukocytes, Year 1, Week 48, n= 254 | -0.01 ± 1.863 |
| Leukocytes, Year 2, Week 24, n= 250 | -0.19 ± 2.087 |
| Leukocytes, Year 2, Week 48, n= 233 | -0.27 ± 2.19 |
| Leukocytes, Year 3, Week 24, n= 219 | -0.33 ± 1.959 |
| Leukocytes, Year 3, Week 48, n= 211 | -0.42 ± 1.876 |
| Leukocytes, Year 4, Week 24, n= 210 | -0.29 ± 2.205 |
| Leukocytes, Year 4, Week 48, n= 194 | -0.35 ± 2.207 |
| Leukocytes, Year 5, Week 24, n= 188 | -0.4 ± 2.112 |
| Leukocytes, Year 5, Week 48, n= 184 | -0.18 ± 2.389 |
| Leukocytes, Year 6, Week 24, n= 176 | -0.4 ± 2.161 |
| Leukocytes, Year 6, Week 48, n= 132 | -0.24 ± 2.164 |
| Leukocytes, Year 7, Week 24, n= 122 | -0.22 ± 2.149 |
| Leukocytes, Year 7, Week 48, n= 96 | 0.05 ± 2.388 |
| Leukocytes, Year 8, Week 24, n= 60 | 0.17 ± 2.297 |
| Leukocytes, Year 8, Week 48, n= 29 | -0.63 ± 2.549 |
| Leukocytes, Year 9, Week 24, n= 2 | -3.7 ± 1.273 |
| Leukocytes, Exit, n= 233 | 0.09 ± 2.969 |
| Leukocytes, 8 Week, Follow-Up, n= 106 | -0.11 ± 2.613 |
| Lymphocytes, Year 1, Week 4, n= 257 | 0.076 ± 0.4223 |
| Lymphocytes, Year 1, Week 12, n= 249 | 0.039 ± 0.558 |
| Lymphocytes, Year 1, Week 24, n= 249 | 0.002 ± 0.5023 |
| Lymphocytes, Year 1, Week 36, n= 240 | 0.059 ± 0.5002 |
| Lymphocytes, Year 1, Week 48, n= 254 | -0.02 ± 0.5129 |
| Lymphocytes, Year 2, Week 24, n= 250 | -0.073 ± 0.5033 |
| Lymphocytes, Year 2, Week 48, n= 233 | -0.036 ± 0.5299 |
| Lymphocytes, Year 3, Week 24, n= 219 | 0.002 ± 0.5621 |
| Lymphocytes, Year 3, Week 48, n= 211 | -0.028 ± 0.572 |
| Lymphocytes, Year 4, Week 24, n= 210 | -0.036 ± 0.5809 |
| Lymphocytes, Year 4, Week 48, n= 194 | -0.067 ± 0.5678 |
| Lymphocytes, Year 5, Week 24, n= 188 | -0.07 ± 0.5924 |
| Lymphocytes, Year 5, Week 48, n= 184 | -0.047 ± 0.629 |
| Lymphocytes, Year 6, Week 24, n= 176 | -0.021 ± 0.5876 |
| Lymphocytes, Year 6, Week 48, n= 132 | -0.008 ± 0.5564 |
| Lymphocytes, Year 7, Week 24, n= 122 | 0.011 ± 0.6439 |
| Lymphocytes, Year 7, Week 48, n= 96 | 0.143 ± 0.6619 |
| Lymphocytes, Year 8, Week 24, n= 60 | 0.126 ± 0.6291 |
| Lymphocytes, Year 8, Week 48, n= 29 | 0.059 ± 0.8495 |
| Lymphocytes, Year 9, Week 24, n= 2 | 0.765 ± 1.4354 |
| Lymphocytes, Exit, n= 233 | -0.025 ± 0.6129 |
| Lymphocytes, 8 Week, Follow-Up, n= 106 | 0.029 ± 0.6256 |
| Monocytes, Year 1, Week 4, n= 257 | 0.028 ± 0.1673 |
| Monocytes, Year 1, Week 12, n= 249 | 0.036 ± 0.1694 |
| Monocytes, Year 1, Week 24, n= 249 | 0.024 ± 0.1678 |
| Monocytes, Year 1, Week 36, n= 240 | 0.054 ± 0.1806 |
| Monocytes, Year 1, Week 48, n= 254 | 0.044 ± 0.1754 |
| Monocytes, Year 2, Week 24, n= 250 | 0.053 ± 0.1809 |
| Monocytes, Year 2, Week 48, n= 233 | 0.052 ± 0.1805 |
| Monocytes, Year 3, Week 24, n= 219 | 0.059 ± 0.1809 |
| Monocytes, Year 3, Week 48, n= 211 | 0.071 ± 0.1903 |
| Monocytes, Year 4, Week 24, n= 210 | 0.065 ± 0.1875 |
| Monocytes, Year 4, Week 48, n= 194 | 0.084 ± 0.1782 |
| Monocytes, Year 5, Week 24, n= 188 | 0.095 ± 0.1878 |
| Monocytes, Year 5, Week 48, n= 184 | 0.086 ± 0.1983 |
| Monocytes, Year 6, Week 24, n= 176 | 0.072 ± 0.1826 |
| Monocytes, Year 6, Week 48, n= 132 | 0.049 ± 0.1808 |
| Monocytes, Year 7, Week 24, n= 122 | 0.098 ± 0.1996 |
| Monocytes, Year 7, Week 48, n= 96 | 0.097 ± 0.2032 |
| Monocytes, Year 8, Week 24, n= 60 | 0.101 ± 0.1909 |
| Monocytes, Year 8, Week 48, n= 29 | 0.024 ± 0.2074 |
| Monocytes, Year 9, Week 24, n= 2 | 0.03 ± 0.3818 |
| Monocytes, Exit, n= 233 | 0.075 ± 0.1846 |
| Monocytes, 8 Week, Follow-Up, n= 106 | 0.093 ± 0.1958 |
| Neutrophils, Year 1, Week 4, n= 257 | -0.027 ± 1.6734 |
| Neutrophils, Year 1, Week 12, n= 249 | 0.1 ± 1.7293 |
| Neutrophils, Year 1, Week 24, n= 249 | -0.059 ± 1.8685 |
| Neutrophils, Year 1, Week 36, n= 240 | -0.086 ± 2.1086 |
| Neutrophils, Year 1, Week 48, n= 254 | -0.037 ± 1.7955 |
| Neutrophils, Year 2, Week 24, n= 250 | -0.176 ± 2.0209 |
| Neutrophils, Year 2, Week 48, n= 233 | -0.283 ± 2.1226 |
| Neutrophils, Year 3, Week 24, n= 219 | -0.397 ± 1.8521 |
| Neutrophils, Year 3, Week 48, n= 211 | -0.443 ± 1.763 |
| Neutrophils, Year 4, Week 24, n= 210 | -0.288 ± 2.1214 |
| Neutrophils, Year 4, Week 48, n= 194 | -0.342 ± 2.1425 |
| Neutrophils, Year 5, Week 24, n= 188 | -0.392 ± 1.9654 |
| Neutrophils, Year 5, Week 48, n= 184 | -0.207 ± 2.2312 |
| Neutrophils, Year 6, Week 24, n= 176 | -0.424 ± 2.0787 |
| Neutrophils, Year 6, Week 48, n= 132 | -0.251 ± 2.1415 |
| Neutrophils, Year 7, Week 24, n= 122 | -0.315 ± 2.1382 |
| Neutrophils, Year 7, Week 48, n= 96 | -0.176 ± 2.3755 |
| Neutrophils, Year 8, Week 24, n= 60 | -0.025 ± 2.2303 |
| Neutrophils, Year 8, Week 48, n= 29 | -0.681 ± 2.4214 |
| Neutrophils, Year 9, Week 24, n= 2 | -4.44 ± 0.5798 |
| Neutrophils, Exit, n= 233 | 0.058 ± 2.9836 |
| Neutrophils, 8 Week, Follow-Up, n= 106 | -0.214 ± 2.5793 |
| Neutrophils segmented, Year 1, Week 4, n= 257 | -0.028 ± 1.6685 |
| Neutrophils segmented, Year 1, Week 12, n= 249 | 0.098 ± 1.7212 |
| Neutrophils segmented, Year 1, Week 24, n= 249 | -0.059 ± 1.8683 |
| Neutrophils segmented, Year 1, Week 36, n= 240 | -0.086 ± 2.1097 |
| Neutrophils segmented, Year 1, Week 48, n= 254 | -0.044 ± 1.8014 |
| Neutrophils segmented, Year 2, Week 24, n= 250 | -0.177 ± 2.0163 |
| Neutrophils segmented, Year 2, Week 48, n= 233 | -0.284 ± 2.1204 |
| Neutrophils segmented, Year 3, Week 24, n= 219 | -0.397 ± 1.8509 |
| Neutrophils segmented, Year 3, Week 48, n= 211 | -0.444 ± 1.7607 |
| Neutrophils segmented, Year 4, Week 24, n= 210 | -0.286 ± 2.1249 |
| Neutrophils segmented, Year 4, Week 48, n= 194 | -0.342 ± 2.1464 |
| Neutrophils segmented, Year 5, Week 24, n= 188 | -0.39 ± 1.9703 |
| Neutrophils segmented, Year 5, Week 48, n= 184 | -0.207 ± 2.2273 |
| Neutrophils segmented, Year 6, Week 24, n= 176 | -0.422 ± 2.0826 |
| Neutrophils segmented, Year 6, Week 48, n= 132 | -0.249 ± 2.1432 |
| Neutrophils segmented, Year 7, Week 24, n= 122 | -0.313 ± 2.1378 |
| Neutrophils segmented, Year 7, Week 48, n= 96 | -0.179 ± 2.3698 |
| Neutrophils segmented, Year 8, Week 24, n= 60 | -0.025 ± 2.2303 |
| Neutrophils segmented, Year 8, Week 48, n= 29 | -0.681 ± 2.4214 |
| Neutrophils segmented, Year 9, Week 24, n= 2 | -4.44 ± 0.5798 |
| Neutrophils segmented, Exit, n= 233 | 0.046 ± 2.8796 |
| Neutrophils segmented, 8 Week, Follow-Up, n= 106 | -0.215 ± 2.5788 |
| Platelets, Year 1, Week 4, n= 254 | 2.9 ± 35.71 |
| Platelets, Year 1, Week 12, n= 248 | -1.1 ± 42.04 |
| Platelets, Year 1, Week 24, n= 247 | -2 ± 41.13 |
| Platelets, Year 1, Week 36, n= 238 | -5.9 ± 46.11 |
| Platelets, Year 1, Week 48, n= 252 | -8.4 ± 46.36 |
| Platelets, Year 2, Week 24, n= 249 | -17.5 ± 56.18 |
| Platelets, Year 2, Week 48, n= 233 | -18.8 ± 56.8 |
| Platelets, Year 3, Week 24, n= 218 | -17 ± 56.86 |
| Platelets, Year 3, Week 48, n= 210 | -22.4 ± 57.11 |
| Platelets, Year 4, Week 24, n= 210 | -14.6 ± 64.11 |
| Platelets, Year 4, Week 48, n= 193 | -17 ± 60.26 |
| Platelets, Year 5, Week 24, n= 188 | -19 ± 65.99 |
| Platelets, Year 5, Week 48, n= 184 | -17.6 ± 65.69 |
| Platelets, Year 6, Week 24, n= 175 | -18.9 ± 62.88 |
| Platelets, Year 6, Week 48, n= 132 | -23.7 ± 67.73 |
| Platelets, Year 7, Week 24, n= 121 | -14 ± 77.75 |
| Platelets, Year 7, Week 48, n= 96 | -24.7 ± 64.56 |
| Platelets, Year 8, Week 24, n= 60 | -30.5 ± 65.89 |
| Platelets, Year 8, Week 48, n= 29 | -40.7 ± 62.84 |
| Platelets, Year 9, Week 24, n= 2 | 37 ± 83.44 |
| Platelets, Exit, n= 233 | -9.4 ± 59.82 |
| Platelets, 8 Week, Follow-Up, n= 106 | -8 ± 70.29 |
Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Trillions cells per liter | Belimumab 10 mg/kg IV |
|---|---|
| Erythrocytes, Year 1, Week 4, n= 257 | 0 ± 0.243 |
| Erythrocytes, Year 1, Week 12, n= 249 | 0.01 ± 0.284 |
| Erythrocytes, Year 1, Week 24, n= 250 | 0.04 ± 0.291 |
| Erythrocytes, Year 1, Week 36, n= 240 | 0.03 ± 0.309 |
| Erythrocytes, Year 1, Week 48, n= 254 | 0.06 ± 0.337 |
| Erythrocytes, Year 2, Week 24, n= 249 | 0.06 ± 0.341 |
| Erythrocytes, Year 2, Week 48, n= 233 | 0.04 ± 0.338 |
| Erythrocytes, Year 3, Week 24, n= 219 | 0.06 ± 0.361 |
| Erythrocytes, Year 3, Week 48, n= 211 | 0.04 ± 0.362 |
| Erythrocytes, Year 4, Week 24, n= 210 | 0.03 ± 0.37 |
| Erythrocytes, Year 4, Week 48, n= 194 | 0.07 ± 0.376 |
| Erythrocytes, Year 5, Week 24, n= 189 | 0.08 ± 0.395 |
| Erythrocytes, Year 5, Week 48, n= 184 | 0.1 ± 0.412 |
| Erythrocytes, Year 6, Week 24, n= 176 | 0.13 ± 0.405 |
| Erythrocytes, Year 6, Week 48, n= 132 | 0.19 ± 0.393 |
| Erythrocytes, Year 7, Week 24, n= 122 | 0.2 ± 0.438 |
| Erythrocytes, Year 7, Week 48, n= 96 | 0.19 ± 0.441 |
| Erythrocytes, Year 8, Week 24, n= 60 | 0.25 ± 0.404 |
| Erythrocytes, Year 8, Week 48, n= 29 | 0.39 ± 0.403 |
| Erythrocytes, Year 9, Week 24, n= 2 | 0.1 ± 0 |
| Erythrocytes, Exit, n= 233 | 0.26 ± 0.398 |
| Erythrocytes, 8 Week, Follow-Up, n= 106 | 0.2 ± 0.415 |
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage | Belimumab 10 mg/kg IV |
|---|---|
| Hematocrit, Year 1, Week 4, n= 257 | 0.16 ± 2.247 |
| Hematocrit, Year 1, Week 12, n= 249 | 0.11 ± 2.62 |
| Hematocrit, Year 1, Week 24, n= 250 | 0.31 ± 2.683 |
| Hematocrit, Year 1, Week 36, n= 240 | 0.2 ± 2.836 |
| Hematocrit, Year 1, Week 48, n= 254 | 0.73 ± 3.087 |
| Hematocrit, Year 2, Week 24, n= 249 | 0.81 ± 3.321 |
| Hematocrit, Year 2, Week 48, n= 233 | 1.09 ± 3.433 |
| Hematocrit, Year 3, Week 24, n= 219 | 1.4 ± 3.604 |
| Hematocrit, Year 3, Week 48, n= 211 | 1.53 ± 3.545 |
| Hematocrit, Year 4, Week 24, n= 210 | 1.39 ± 3.448 |
| Hematocrit, Year 4, Week 48, n= 194 | 1.67 ± 3.414 |
| Hematocrit, Year 5, Week 24, n= 189 | 1.78 ± 3.596 |
| Hematocrit, Year 5, Week 48, n= 184 | 1.98 ± 3.943 |
| Hematocrit, Year 6, Week 24, n= 176 | 2.16 ± 3.94 |
| Hematocrit, Year 6, Week 48, n= 132 | 2.49 ± 3.561 |
| Hematocrit, Year 7, Week 24, n= 122 | 2.34 ± 4.166 |
| Hematocrit, Year 7, Week 48, n= 96 | 1.86 ± 4.108 |
| Hematocrit, Year 8, Week 24, n= 60 | 2.68 ± 3.807 |
| Hematocrit, Year 8, Week 48, n= 29 | 3.49 ± 3.554 |
| Hematocrit, Year 9, Week 24, n= 2 | 0.7 ± 0.99 |
| Hematocrit, Exit, n= 233 | 3.25 ± 3.613 |
| Hematocrit, 8 Week, Follow-Up, n= 106 | 3.04 ± 3.478 |
Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Grams per liter | Belimumab 10 mg/kg IV |
|---|---|
| Hemoglobin, Year 1, Week 4, n= 257 | 0 ± 7.03 |
| Hemoglobin, Year 1, Week 12, n= 249 | 0.3 ± 8.17 |
| Hemoglobin, Year 1, Week 24, n= 250 | 0.5 ± 8.81 |
| Hemoglobin, Year 1, Week 36, n= 240 | 0.5 ± 9.51 |
| Hemoglobin, Year 1, Week 48, n= 254 | 2.1 ± 10.2 |
| Hemoglobin, Year 2, Week 24, n= 250 | 2.5 ± 11.07 |
| Hemoglobin, Year 2, Week 48, n= 233 | 2.4 ± 11.76 |
| Hemoglobin, Year 3, Week 24, n= 219 | 3.7 ± 11.93 |
| Hemoglobin, Year 3, Week 48, n= 211 | 3.9 ± 11.86 |
| Hemoglobin, Year 4, Week 24, n= 210 | 2.5 ± 11.91 |
| Hemoglobin, Year 4, Week 48, n= 194 | 3.2 ± 11.82 |
| Hemoglobin, Year 5, Week 24, n= 189 | 3.7 ± 12.44 |
| Hemoglobin, Year 5, Week 48, n= 184 | 3.7 ± 13.71 |
| Hemoglobin, Year 6, Week 24, n= 176 | 3.7 ± 13.6 |
| Hemoglobin, Year 6, Week 48, n= 132 | 4.2 ± 13.13 |
| Hemoglobin, Year 7, Week 24, n= 122 | 3.3 ± 14.73 |
| Hemoglobin, Year 7, Week 48, n= 96 | 2.6 ± 14.98 |
| Hemoglobin, Year 8, Week 24, n= 60 | 5.2 ± 12.78 |
| Hemoglobin, Year 8, Week 48, n= 29 | 8.4 ± 12.98 |
| Hemoglobin, Year 9, Week 24, n= 2 | -3 ± 2.83 |
| Hemoglobin, Exit, n= 233 | 7.2 ± 12.46 |
| Hemoglobin, 8 Week, Follow-Up, n= 106 | 6.5 ± 11.93 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Grams per liter | Belimumab 10 mg/kg IV |
|---|---|
| Albumin, Year 1, Week 4, n= 251 | -0.3 ± 2.17 |
| Albumin, Year 1, Week 12, n= 248 | 0.1 ± 2.53 |
| Albumin, Year 1, Week 24, n= 246 | 0.3 ± 2.47 |
| Albumin, Year 1, Week 36, n= 238 | 0.4 ± 2.69 |
| Albumin, Year 1, Week 48, n= 250 | 1.1 ± 2.88 |
| Albumin, Year 2, Week 24, n= 248 | 1.1 ± 3.18 |
| Albumin, Year 2, Week 48, n= 233 | 1.2 ± 3.25 |
| Albumin, Year 3, Week 24, n= 218 | 1.3 ± 3.41 |
| Albumin, Year 3, Week 48, n= 209 | 1.4 ± 3.65 |
| Albumin, Year 4, Week 24, n= 207 | 1.3 ± 3.6 |
| Albumin, Year 4, Week 48, n= 194 | 1.5 ± 3.5 |
| Albumin, Year 5, Week 24, n= 184 | 1.7 ± 3.76 |
| Albumin, Year 5, Week 48, n= 178 | 2 ± 3.69 |
| Albumin, Year 6, Week 24, n= 175 | 1.8 ± 4.05 |
| Albumin, Year 6, Week 48, n= 134 | 1.8 ± 4.09 |
| Albumin, Year 7, Week 24, n= 123 | 1.4 ± 4.14 |
| Albumin, Year 7, Week 48, n= 97 | 1.6 ± 4.19 |
| Albumin, Year 8, Week 24, n= 60 | 2 ± 4.4 |
| Albumin, Year 8, Week 48, n= 28 | 2.9 ± 3.92 |
| Albumin, Year 9, Week 24, n= 2 | 1 ± 0 |
| Albumin, Exit, n= 235 | 2.2 ± 3.59 |
| Albumin, 8 Week, Follow-Up, n= 107 | 1.8 ± 3.77 |
| Protein, Year 1, Week 4, n= 251 | -1.3 ± 3.73 |
| Protein, Year 1, Week 12, n= 248 | -1.9 ± 4.41 |
| Protein, Year 1, Week 24, n= 246 | -2.1 ± 4.31 |
| Protein, Year 1, Week 36, n= 238 | -2.6 ± 4.59 |
| Protein, Year 1, Week 48, n= 250 | -1.8 ± 4.91 |
| Protein, Year 2, Week 24, n= 248 | -2.2 ± 4.9 |
| Protein, Year 2, Week 48, n= 233 | -2.6 ± 5.08 |
| Protein, Year 3, Week 24, n= 218 | -2.6 ± 5 |
| Protein, Year 3, Week 48, n= 209 | -3 ± 5.36 |
| Protein, Year 4, Week 24, n= 207 | -3.4 ± 5.3 |
| Protein, Year 4, Week 48, n= 194 | -3.6 ± 5.22 |
| Protein, Year 5, Week 24, n= 184 | -3.4 ± 5.44 |
| Protein, Year 5, Week 48, n= 178 | -3.4 ± 5.16 |
| Protein, Year 6, Week 24, n= 175 | -4 ± 5.55 |
| Protein, Year 6, Week 48, n= 134 | -3.5 ± 5.81 |
| Protein, Year 7, Week 24, n= 123 | -4.3 ± 5.56 |
| Protein, Year 7, Week 48, n= 97 | -4.3 ± 5.87 |
| Protein, Year 8, Week 24, n= 60 | -4.1 ± 5.78 |
| Protein, Year 8, Week 48, n= 28 | -3 ± 5.18 |
| Protein, Year 9, Week 24, n= 2 | -1.5 ± 2.12 |
| Protein, Exit, n= 235 | -2.6 ± 5.53 |
| Protein, 8 Week, Follow-Up, n= 107 | -3.1 ± 6.19 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Millimoles per liter | Belimumab 10 mg/kg IV |
|---|---|
| Blood urea nitrogen, Year 1, Week 4, n= 251 | 0.026 ± 1.4283 |
| Blood urea nitrogen, Year 1, Week 12, n= 248 | -0.1695 ± 1.4782 |
| Blood urea nitrogen, Year 1, Week 24, n= 246 | -0.1612 ± 1.9011 |
| Blood urea nitrogen, Year 1, Week 36, n= 238 | -0.1732 ± 1.5648 |
| Blood urea nitrogen, Year 1, Week 48, n= 250 | -0.1013 ± 1.5557 |
| Blood urea nitrogen, Year 2, Week 24, n= 248 | -0.1873 ± 1.6796 |
| Blood urea nitrogen, Year 2, Week 48, n= 233 | -0.0134 ± 1.7024 |
| Blood urea nitrogen, Year 3, Week 24, n= 218 | -0.0552 ± 1.7117 |
| Blood urea nitrogen, Year 3, Week 48, n= 209 | -0.0472 ± 1.6693 |
| Blood urea nitrogen, Year 4, Week 24, n= 207 | -0.09 ± 1.6775 |
| Blood urea nitrogen, Year 4, Week 48, n= 194 | -0.1162 ± 1.721 |
| Blood urea nitrogen, Year 5, Week 24, n= 184 | -0.0331 ± 1.6526 |
| Blood urea nitrogen, Year 5, Week 48, n= 178 | 0.0176 ± 1.7712 |
| Blood urea nitrogen, Year 6, Week 24, n= 175 | -0.0029 ± 1.6054 |
| Blood urea nitrogen, Year 6, Week 48, n= 134 | -0.0858 ± 1.6972 |
| Blood urea nitrogen, Year 7, Week 24, n= 123 | 0.0246 ± 1.6668 |
| Blood urea nitrogen, Year 7, Week 48, n= 97 | -0.008 ± 1.6683 |
| Blood urea nitrogen, Year 8, Week 24, n= 60 | -0.1152 ± 1.5362 |
| Blood urea nitrogen, Year 8, Week 48, n= 28 | -0.1603 ± 1.5417 |
| Blood urea nitrogen, Year 9, Week 24, n= 2 | -0.1805 ± 1.06 |
| Blood urea nitrogen, Exit, n= 235 | 0.0501 ± 1.7369 |
| Blood urea nitrogen, 8 Week, Follow-Up, n= 107 | 0.3248 ± 2.2109 |
| Glucose, Year 1, Week 4, n= 251 | 0.1088 ± 1.1734 |
| Glucose, Year 1, Week 12, n= 248 | 0.2006 ± 1.1712 |
| Glucose, Year 1, Week 24, n= 246 | 0.0881 ± 1.2279 |
| Glucose, Year 1, Week 36, n= 238 | 0.2158 ± 1.2519 |
| Glucose, Year 1, Week 48, n= 250 | 0.1482 ± 1.5029 |
| Glucose, Year 2, Week 24, n= 248 | 0.1146 ± 1.3072 |
| Glucose, Year 2, Week 48, n= 233 | 0.323 ± 1.5426 |
| Glucose, Year 3, Week 24, n= 218 | 0.1927 ± 1.4319 |
| Glucose, Year 3, Week 48, n= 209 | 0.1719 ± 1.4829 |
| Glucose, Year 4, Week 24, n= 207 | 0.2737 ± 1.6169 |
| Glucose, Year 4, Week 48, n= 194 | 0.2523 ± 2.1698 |
| Glucose, Year 5, Week 24, n= 184 | 0.2579 ± 1.4792 |
| Glucose, Year 5, Week 48, n= 178 | 0.2964 ± 1.7205 |
| Glucose, Year 6, Week 24, n= 175 | 0.2903 ± 1.7746 |
| Glucose, Year 6, Week 48, n= 134 | 0.3897 ± 1.7503 |
| Glucose, Year 7, Week 24, n= 123 | 0.297 ± 2.257 |
| Glucose, Year 7, Week 48, n= 97 | 0.5098 ± 1.8839 |
| Glucose, Year 8, Week 24, n= 60 | 0.449 ± 1.9609 |
| Glucose, Year 8, Week 48, n= 28 | 0.7571 ± 2.2408 |
| Glucose, Year 9, Week 24, n= 2 | 0.8845 ± 0.4094 |
| Glucose, Exit, n= 235 | 0.2986 ± 1.3871 |
| Glucose, 8 Week, Follow-Up, n= 107 | 0.3354 ± 1.4114 |
| Calcium, Year 1, Week 4, n= 242 | 0.0071 ± 0.0888 |
| Calcium, Year 1, Week 12, n= 247 | -0.0043 ± 0.0872 |
| Calcium, Year 1, Week 24, n= 244 | -0.0023 ± 0.0889 |
| Calcium, Year 1, Week 36, n= 235 | -0.0156 ± 0.0884 |
| Calcium, Year 1, Week 48, n= 250 | 0.0007 ± 0.0896 |
| Calcium, Year 2, Week 24, n= 246 | -0.0017 ± 0.0946 |
| Calcium, Year 2, Week 48, n= 231 | -0.0019 ± 0.0922 |
| Calcium, Year 3, Week 24, n= 214 | -0.0009 ± 0.09 |
| Calcium, Year 3, Week 48, n= 205 | -0.0109 ± 0.1004 |
| Calcium, Year 4, Week 24, n= 204 | -0.0115 ± 0.095 |
| Calcium, Year 4, Week 48, n= 191 | -0.0072 ± 0.0889 |
| Calcium, Year 5, Week 24, n= 184 | -0.0181 ± 0.0986 |
| Calcium, Year 5, Week 48, n= 176 | -0.0011 ± 0.0912 |
| Calcium, Year 6, Week 24, n= 172 | -0.0107 ± 0.0977 |
| Calcium, Year 6, Week 48, n= 134 | 0.0007 ± 0.0925 |
| Calcium, Year 7, Week 24, n= 121 | 0.0014 ± 0.0873 |
| Calcium, Year 7, Week 48, n= 97 | 0.0063 ± 0.0964 |
| Calcium, Year 8, Week 24, n= 60 | -0.0123 ± 0.0788 |
| Calcium, Year 8, Week 48, n= 28 | 0.0021 ± 0.0935 |
| Calcium, Year 9, Week 24, n= 2 | -0.005 ± 0.0354 |
| Calcium, Exit, n= 235 | 0.0151 ± 0.0923 |
| Calcium, 8 Week, Follow-Up, n= 107 | 0.0046 ± 0.1029 |
| Carbon dioxide, Year 1, Week 4, n= 243 | -0.2 ± 2.72 |
| Carbon dioxide, Year 1, Week 12, n= 245 | -0.4 ± 2.62 |
| Carbon dioxide, Year 1, Week 24, n= 244 | -0.2 ± 2.51 |
| Carbon dioxide, Year 1, Week 36, n= 234 | -0.1 ± 2.67 |
| Carbon dioxide, Year 1, Week 48, n= 250 | -0.2 ± 2.64 |
| Carbon dioxide, Year 2, Week 24, n= 246 | 0 ± 2.58 |
| Carbon dioxide, Year 2, Week 48, n= 231 | -0.5 ± 2.78 |
| Carbon dioxide, Year 3, Week 24, n= 215 | -0.5 ± 2.75 |
| Carbon dioxide, Year 3, Week 48, n= 205 | -0.9 ± 2.82 |
| Carbon dioxide, Year 4, Week 24, n= 204 | -0.6 ± 2.7 |
| Carbon dioxide, Year 4, Week 48, n= 191 | -0.6 ± 2.79 |
| Carbon dioxide, Year 5, Week 24, n= 184 | -0.9 ± 2.68 |
| Carbon dioxide, Year 5, Week 48, n= 176 | -0.7 ± 2.73 |
| Carbon dioxide, Year 6, Week 24, n= 172 | -0.8 ± 2.62 |
| Carbon dioxide, Year 6, Week 48, n= 134 | -0.7 ± 3.23 |
| Carbon dioxide, Year 7, Week 24, n= 121 | -0.7 ± 2.84 |
| Carbon dioxide, Year 7, Week 48, n= 97 | -0.3 ± 3.14 |
| Carbon dioxide, Year 8, Week 24, n= 60 | -0.5 ± 3.17 |
| Carbon dioxide, Year 8, Week 48, n= 28 | -0.7 ± 2.87 |
| Carbon dioxide, Year 9, Week 24, n= 2 | -1 ± 1.41 |
| Carbon dioxide, Exit, n= 235 | 0.1 ± 2.74 |
| Carbon dioxide, 8 Week, Follow-Up, n= 107 | 0 ± 2.55 |
| Chloride, Year 1, Week 4, n= 251 | 0.2 ± 2.8 |
| Chloride, Year 1, Week 12, n= 248 | 0.1 ± 2.53 |
| Chloride, Year 1, Week 24, n= 246 | 0.3 ± 2.31 |
| Chloride, Year 1, Week 36, n= 238 | 0.5 ± 2.43 |
| Chloride, Year 1, Week 48, n= 250 | 0 ± 2.53 |
| Chloride, Year 2, Week 24, n= 248 | 0.1 ± 2.6 |
| Chloride, Year 2, Week 48, n= 233 | 0.1 ± 3.03 |
| Chloride, Year 3, Week 24, n= 218 | -0.1 ± 3.01 |
| Chloride, Year 3, Week 48, n= 209 | 0.1 ± 3.06 |
| Chloride, Year 4, Week 24, n= 207 | -0.4 ± 3.28 |
| Chloride, Year 4, Week 48, n= 194 | -0.3 ± 2.83 |
| Chloride, Year 5, Week 24, n= 184 | -0.3 ± 3.06 |
| Chloride, Year 5, Week 48, n= 178 | -0.1 ± 3.02 |
| Chloride, Year 6, Week 24, n= 175 | 0 ± 3.11 |
| Chloride, Year 6, Week 48, n= 134 | 0.3 ± 2.89 |
| Chloride, Year 7, Week 24, n= 123 | 0.4 ± 3.1 |
| Chloride, Year 7, Week 48, n= 97 | 0.5 ± 3.28 |
| Chloride, Year 8, Week 24, n= 60 | 0.5 ± 3.21 |
| Chloride, Year 8, Week 48, n= 28 | 1.1 ± 2.49 |
| Chloride, Year 9, Week 24, n= 2 | 1.5 ± 2.12 |
| Chloride, Exit, n= 235 | -0.5 ± 2.96 |
| Chloride, 8 Week, Follow-Up, n= 107 | 0.1 ± 2.65 |
| Magnesium, Year 1, Week 4, n= 251 | 0.002 ± 0.0673 |
| Magnesium, Year 1, Week 12, n= 248 | -0.005 ± 0.0625 |
| Magnesium, Year 1, Week 24, n= 246 | 0.004 ± 0.0599 |
| Magnesium, Year 1, Week 36, n= 238 | 0.001 ± 0.066 |
| Magnesium, Year 1, Week 48, n= 250 | 0.001 ± 0.0677 |
| Magnesium, Year 2, Week 24, n= 248 | 0.003 ± 0.0709 |
| Magnesium, Year 2, Week 48, n= 233 | 0.003 ± 0.0699 |
| Magnesium, Year 3, Week 24, n= 218 | 0.007 ± 0.0719 |
| Magnesium, Year 3, Week 48, n= 209 | 0.011 ± 0.0681 |
| Magnesium, Year 4, Week 24, n= 207 | 0.009 ± 0.0682 |
| Magnesium, Year 4, Week 48, n= 194 | 0.012 ± 0.0692 |
| Magnesium, Year 5, Week 24, n= 184 | 0.017 ± 0.062 |
| Magnesium, Year 5, Week 48, n= 178 | 0.014 ± 0.0622 |
| Magnesium, Year 6, Week 24, n= 175 | 0.017 ± 0.067 |
| Magnesium, Year 6, Week 48, n= 134 | 0.003 ± 0.0664 |
| Magnesium, Year 7, Week 24, n= 123 | 0.004 ± 0.0691 |
| Magnesium, Year 7, Week 48, n= 97 | 0.001 ± 0.0681 |
| Magnesium, Year 8, Week 24, n= 60 | -0.006 ± 0.0644 |
| Magnesium, Year 8, Week 48, n= 28 | 0.016 ± 0.0599 |
| Magnesium, Year 9, Week 24, n= 2 | 0.02 ± 0.0283 |
| Magnesium, Exit, n= 235 | 0.03 ± 0.0676 |
| Magnesium, 8 Week, Follow-Up, n= 107 | 0.028 ± 0.0728 |
| Phosphate, Year 1, Week 4, n= 251 | 0.0165 ± 0.1857 |
| Phosphate, Year 1, Week 12, n= 248 | -0.0065 ± 0.1851 |
| Phosphate, Year 1, Week 24, n= 246 | 0.0106 ± 0.2027 |
| Phosphate, Year 1, Week 36, n= 238 | -0.0039 ± 0.1825 |
| Phosphate, Year 1, Week 48, n= 250 | 0.0019 ± 0.1926 |
| Phosphate, Year 2, Week 24, n= 248 | -0.0133 ± 0.2219 |
| Phosphate, Year 2, Week 48, n= 233 | 0.0099 ± 0.1968 |
| Phosphate, Year 3, Week 24, n= 218 | 0.0033 ± 0.2129 |
| Phosphate, Year 3, Week 48, n= 209 | 0.0017 ± 0.221 |
| Phosphate, Year 4, Week 24, n= 207 | -0.0022 ± 0.2145 |
| Phosphate, Year 4, Week 48, n= 194 | -0.0102 ± 0.1765 |
| Phosphate, Year 5, Week 24, n= 184 | -0.015 ± 0.1899 |
| Phosphate, Year 5, Week 48, n= 178 | -0.0035 ± 0.1892 |
| Phosphate, Year 6, Week 24, n= 175 | -0.004 ± 0.2153 |
| Phosphate, Year 6, Week 48, n= 134 | -0.0139 ± 0.2097 |
| Phosphate, Year 7, Week 24, n= 123 | 0.0296 ± 0.1962 |
| Phosphate, Year 7, Week 48, n= 97 | 0.031 ± 0.1875 |
| Phosphate, Year 8, Week 24, n= 60 | -0.0223 ± 0.2186 |
| Phosphate, Year 8, Week 48, n= 28 | -0.0054 ± 0.2093 |
| Phosphate, Year 9, Week 24, n= 2 | 0.1467 ± 0.1893 |
| Phosphate, Exit, n= 235 | 0.0161 ± 0.2151 |
| Phosphate, 8 Week, Follow-Up, n= 107 | 0.0438 ± 0.2131 |
| Potassium, Year 1, Week 4, n= 242 | 0.07 ± 0.407 |
| Potassium, Year 1, Week 12, n= 245 | 0.02 ± 0.412 |
| Potassium, Year 1, Week 24, n= 244 | 0.02 ± 0.409 |
| Potassium, Year 1, Week 36, n= 234 | 0.03 ± 0.427 |
| Potassium, Year 1, Week 48, n= 250 | -0.04 ± 0.413 |
| Potassium, Year 2, Week 24, n= 246 | 0.01 ± 0.42 |
| Potassium, Year 2, Week 48, n= 231 | 0.02 ± 0.426 |
| Potassium, Year 3, Week 24, n= 215 | 0.01 ± 0.418 |
| Potassium, Year 3, Week 48, n= 205 | 0.01 ± 0.466 |
| Potassium, Year 4, Week 24, n= 204 | -0.02 ± 0.409 |
| Potassium, Year 4, Week 48, n= 191 | 0.04 ± 0.417 |
| Potassium, Year 5, Week 24, n= 184 | 0 ± 0.406 |
| Potassium, Year 5, Week 48, n= 176 | 0.06 ± 0.427 |
| Potassium, Year 6, Week 24, n= 172 | -0.03 ± 0.431 |
| Potassium, Year 6, Week 48, n= 134 | 0.06 ± 0.438 |
| Potassium, Year 7, Week 24, n= 121 | 0.04 ± 0.379 |
| Potassium, Year 7, Week 48, n= 97 | 0.06 ± 0.387 |
| Potassium, Year 8, Week 24, n= 60 | 0 ± 0.354 |
| Potassium, Year 8, Week 48, n= 28 | 0.1 ± 0.401 |
| Potassium, Year 9, Week 24, n= 2 | 0.05 ± 0.212 |
| Potassium, Exit, n= 235 | 0.11 ± 0.431 |
| Potassium, 8 Week, Follow-Up, n= 107 | 0.07 ± 0.493 |
| Sodium, Year 1, Week 4, n= 251 | 0.4 ± 2.67 |
| Sodium, Year 1, Week 12, n= 248 | 0 ± 2.67 |
| Sodium, Year 1, Week 24, n= 246 | 0.3 ± 2.02 |
| Sodium, Year 1, Week 36, n= 238 | 0.3 ± 2.46 |
| Sodium, Year 1, Week 48, n= 250 | -0.1 ± 2.06 |
| Sodium, Year 2, Week 24, n= 248 | 0 ± 2.19 |
| Sodium, Year 2, Week 48, n= 233 | 0 ± 2.58 |
| Sodium, Year 3, Week 24, n= 218 | -0.1 ± 2.18 |
| Sodium, Year 3, Week 48, n= 209 | 0.4 ± 2.44 |
| Sodium, Year 4, Week 24, n= 207 | 0.2 ± 2.54 |
| Sodium, Year 4, Week 48, n= 194 | 0.1 ± 2.36 |
| Sodium, Year 5, Week 24, n= 184 | 0.1 ± 2.19 |
| Sodium, Year 5, Week 48, n= 178 | 0 ± 2.37 |
| Sodium, Year 6, Week 24, n= 175 | 0.1 ± 2.33 |
| Sodium, Year 6, Week 48, n= 134 | 0.3 ± 2.72 |
| Sodium, Year 7, Week 24, n= 123 | 0.3 ± 2.97 |
| Sodium, Year 7, Week 48, n= 97 | 0.3 ± 2.49 |
| Sodium, Year 8, Week 24, n= 60 | 0.2 ± 2.32 |
| Sodium, Year 8, Week 48, n= 28 | 0.4 ± 1.95 |
| Sodium, Year 9, Week 24, n= 2 | -1 ± 1.41 |
| Sodium, Exit, n= 235 | 0.1 ± 2.32 |
| Sodium, 8 Week, Follow-Up, n= 107 | 0.8 ± 2.33 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Micromoles per liter | Belimumab 10 mg/kg IV |
|---|---|
| Creatinine, Year 1, Week 4, n= 250 | -0.2 ± 4.69 |
| Creatinine, Year 1, Week 12, n= 248 | -0.5 ± 4.86 |
| Creatinine, Year 1, Week 24, n= 246 | -0.6 ± 5.31 |
| Creatinine, Year 1, Week 36, n= 237 | -0.4 ± 5.07 |
| Creatinine, Year 1, Week 48, n= 250 | -0.2 ± 5.29 |
| Creatinine, Year 2, Week 24, n= 248 | -0.2 ± 5.76 |
| Creatinine, Year 2, Week 48, n= 233 | 0.3 ± 4.78 |
| Creatinine, Year 3, Week 24, n= 218 | 0.8 ± 5.63 |
| Creatinine, Year 3, Week 48, n= 209 | 0.9 ± 5.61 |
| Creatinine, Year 4, Week 24, n= 207 | 1.2 ± 5.86 |
| Creatinine, Year 4, Week 48, n= 194 | 0.9 ± 6.05 |
| Creatinine, Year 5, Week 24, n= 184 | 1 ± 5.52 |
| Creatinine, Year 5, Week 48, n= 178 | 1.2 ± 6.49 |
| Creatinine, Year 6, Week 24, n= 175 | 1.2 ± 5.79 |
| Creatinine, Year 6, Week 48, n= 134 | 1 ± 6.38 |
| Creatinine, Year 7, Week 24, n= 123 | 1.1 ± 5.75 |
| Creatinine, Year 7, Week 48, n= 97 | 0.7 ± 5.42 |
| Creatinine, Year 8, Week 24, n= 60 | 0.8 ± 5.09 |
| Creatinine, Year 8, Week 48, n= 28 | 0.4 ± 5.28 |
| Creatinine, Year 9, Week 24, n= 2 | -0.5 ± 0.71 |
| Creatinine, Exit, n= 235 | 1.1 ± 5.57 |
| Creatinine, 8 Week, Follow-Up, n= 107 | 1.3 ± 5.99 |
| Urate, Year 1, Week 4, n= 251 | -1.653 ± 46.0197 |
| Urate, Year 1, Week 12, n= 248 | -5.5803 ± 52.2256 |
| Urate, Year 1, Week 24, n= 246 | -11.6488 ± 55.2277 |
| Urate, Year 1, Week 36, n= 238 | -9.984 ± 57.2999 |
| Urate, Year 1, Week 48, n= 250 | -4.108 ± 58.0533 |
| Urate, Year 2, Week 24, n= 248 | -6.4785 ± 57.0915 |
| Urate, Year 2, Week 48, n= 233 | -4.6501 ± 60.3008 |
| Urate, Year 3, Week 24, n= 218 | 1.6919 ± 63.7367 |
| Urate, Year 3, Week 48, n= 209 | -4.5543 ± 66.183 |
| Urate, Year 4, Week 24, n= 207 | -4.8112 ± 60.2771 |
| Urate, Year 4, Week 48, n= 194 | -2.0736 ± 60.7226 |
| Urate, Year 5, Week 24, n= 184 | -5.296 ± 65.2308 |
| Urate, Year 5, Week 48, n= 178 | -5.7908 ± 65.6118 |
| Urate, Year 6, Week 24, n= 175 | -2.084 ± 73.3489 |
| Urate, Year 6, Week 48, n= 134 | -8.7672 ± 74.9078 |
| Urate, Year 7, Week 24, n= 123 | -2.0775 ± 72.282 |
| Urate, Year 7, Week 48, n= 97 | -0.1021 ± 60.8139 |
| Urate, Year 8, Week 24, n= 60 | 2.0387 ± 66.4246 |
| Urate, Year 8, Week 48, n= 28 | 1.1266 ± 62.7192 |
| Urate, Year 9, Week 24, n= 2 | -1.782 ± 16.402 |
| Urate, Exit, n= 235 | -7.3728 ± 71.4811 |
| Urate, 8 Week, Follow-Up, n= 107 | -6.6934 ± 84.8414 |
| Bilirubin, Year 1, Week 4, n= 251 | 0.008 ± 2.0889 |
| Bilirubin, Year 1, Week 12, n= 248 | 0.165 ± 2.4872 |
| Bilirubin, Year 1, Week 24, n= 246 | 0.075 ± 2.2546 |
| Bilirubin, Year 1, Week 36, n= 238 | 0.124 ± 2.4316 |
| Bilirubin, Year 1, Week 48, n= 250 | 0.231 ± 2.3675 |
| Bilirubin, Year 2, Week 24, n= 248 | 0.359 ± 2.7306 |
| Bilirubin, Year 2, Week 48, n= 233 | 0.307 ± 3.0385 |
| Bilirubin, Year 3, Week 24, n= 218 | 0.249 ± 2.8298 |
| Bilirubin, Year 3, Week 48, n= 209 | -0.115 ± 2.548 |
| Bilirubin, Year 4, Week 24, n= 207 | -0.276 ± 2.6718 |
| Bilirubin, Year 4, Week 48, n= 194 | -0.156 ± 2.823 |
| Bilirubin, Year 5, Week 24, n= 184 | -0.147 ± 2.8668 |
| Bilirubin, Year 5, Week 48, n= 178 | 0.13 ± 2.7449 |
| Bilirubin, Year 6, Week 24, n= 175 | -0.067 ± 2.7954 |
| Bilirubin, Year 6, Week 48, n= 134 | 0.268 ± 2.6834 |
| Bilirubin, Year 7, Week 24, n= 123 | -0.071 ± 2.7018 |
| Bilirubin, Year 7, Week 48, n= 97 | 0.285 ± 2.85 |
| Bilirubin, Year 8, Week 24, n= 60 | 0.529 ± 2.8249 |
| Bilirubin, Year 8, Week 48, n= 28 | 0.175 ± 2.4435 |
| Bilirubin, Year 9, Week 24, n= 2 | -0.45 ± 1.4142 |
| Bilirubin, Exit, n= 235 | 0.403 ± 2.8268 |
| Bilirubin, 8 Week, Follow-Up, n= 107 | -0.191 ± 3.2759 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Milliliters per second | Belimumab 10 mg/kg IV |
|---|---|
| Creatinine clearance, Year 1, Week 4, n= 251 | -0.022 ± 0.2312 |
| Creatinine clearance, Year 1, Week 12, n= 248 | 0.01 ± 0.2455 |
| Creatinine clearance, Year 1, Week 24, n= 246 | 0.028 ± 0.2831 |
| Creatinine clearance, Year 1, Week 36, n= 238 | 0.034 ± 0.3083 |
| Creatinine clearance, Year 1, Week 48, n= 250 | 0.017 ± 0.306 |
| Creatinine clearance, Year 2, Week 24, n= 248 | 0.047 ± 0.3145 |
| Creatinine clearance, Year 2, Week 48, n= 233 | 0.04 ± 0.3498 |
| Creatinine clearance, Year 3, Week 24, n= 218 | 0.093 ± 0.38 |
| Creatinine clearance, Year 3, Week 48, n= 209 | 0.093 ± 0.3784 |
| Creatinine clearance, Year 4, Week 24, n= 207 | 0.13 ± 0.3981 |
| Creatinine clearance, Year 4, Week 48, n= 194 | 0.084 ± 0.3628 |
| Creatinine clearance, Year 5, Week 24, n= 184 | 0.087 ± 0.3724 |
| Creatinine clearance, Year 5, Week 48, n= 178 | 0.04 ± 0.3652 |
| Creatinine clearance, Year 6, Week 24, n= 175 | 0.035 ± 0.3971 |
| Creatinine clearance, Year 6, Week 48, n= 134 | 0.039 ± 0.3985 |
| Creatinine clearance, Year 7, Week 24, n= 123 | -0.007 ± 0.4482 |
| Creatinine clearance, Year 7, Week 48, n= 97 | 0.005 ± 0.4424 |
| Creatinine clearance, Year 8, Week 24, n= 60 | -0.018 ± 0.4682 |
| Creatinine clearance, Year 8, Week 48, n= 28 | -0.042 ± 0.2808 |
| Creatinine clearance, Year 9, Week 24, n= 2 | -0.083 ± 0.165 |
| Creatinine clearance, Exit, n= 235 | 0.011 ± 0.3986 |
| Creatinine clearance, 8 Week, Follow-Up, n= 106 | 0.036 ± 0.3467 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| BUN/creatinine, Year 1, Week 4, n= 251 | -0.2 ± 4.69 |
| BUN/creatinine, Year 1, Week 12, n= 248 | -0.5 ± 4.86 |
| BUN/creatinine, Year 1, Week 24, n= 246 | -0.6 ± 5.31 |
| BUN/creatinine, Year 1, Week 36, n= 238 | -0.4 ± 5.07 |
| BUN/creatinine, Year 1, Week 48, n= 250 | -0.2 ± 5.29 |
| BUN/creatinine, Year 2, Week 24, n= 248 | -0.2 ± 5.76 |
| BUN/creatinine, Year 2, Week 48, n= 233 | 0.3 ± 4.78 |
| BUN/creatinine, Year 3, Week 24, n= 218 | 0.8 ± 5.63 |
| BUN/creatinine, Year 3, Week 48, n= 209 | 0.9 ± 5.61 |
| BUN/creatinine, Year 4, Week 24, n= 207 | 1.2 ± 5.86 |
| BUN/creatinine, Year 4, Week 48, n= 194 | 0.9 ± 6.05 |
| BUN/creatinine, Year 5, Week 24, n= 184 | 1 ± 5.52 |
| BUN/creatinine, Year 5, Week 48, n= 178 | 1.2 ± 6.49 |
| BUN/creatinine, Year 6, Week 24, n= 175 | 1.2 ± 5.79 |
| BUN/creatinine, Year 6, Week 48, n= 134 | 1 ± 6.38 |
| BUN/creatinine, Year 7, Week 24, n= 123 | 1.1 ± 5.75 |
| BUN/creatinine, Year 7, Week 48, n= 97 | 0.7 ± 5.42 |
| BUN/creatinine, Year 8, Week 24, n= 60 | 0.8 ± 5.09 |
| BUN/creatinine, Year 8, Week 48, n= 28 | 0.4 ± 5.28 |
| BUN/creatinine, Year 9, Week 24, n= 2 | -0.5 ± 0.71 |
| BUN/creatinine, Exit, n= 235 | 1.1 ± 5.57 |
| BUN/creatinine, 8 Week, Follow-Up, n= 107 | 1.3 ± 5.99 |
Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Units per liter | Belimumab 10 mg/kg IV |
|---|---|
| Alanine aminotransferase, Year 1, Week 4, n= 251 | 0.5 ± 14.89 |
| Alanine aminotransferase, Year 1, Week 12, n= 248 | -0.5 ± 11.01 |
| Alanine aminotransferase, Year 1, Week 24, n= 246 | -0.1 ± 12.27 |
| Alanine aminotransferase, Year 1, Week 36, n= 238 | 0.3 ± 14.12 |
| Alanine aminotransferase, Year 1, Week 48, n= 250 | 0.4 ± 14.64 |
| Alanine aminotransferase, Year 2, Week 24, n= 248 | 0.8 ± 12.33 |
| Alanine aminotransferase, Year 2, Week 48, n= 233 | 1.7 ± 16.67 |
| Alanine aminotransferase, Year 3, Week 24, n= 218 | 0.9 ± 12.32 |
| Alanine aminotransferase, Year 3, Week 48, n= 209 | 0.4 ± 14.93 |
| Alanine aminotransferase, Year 4, Week 24, n= 207 | 1.7 ± 17.02 |
| Alanine aminotransferase, Year 4, Week 48, n= 194 | 2.4 ± 24.4 |
| Alanine aminotransferase, Year 5, Week 24, n= 184 | 1.8 ± 15.79 |
| Alanine aminotransferase, Year 5, Week 48, n= 178 | 0.3 ± 17.15 |
| Alanine aminotransferase, Year 6, Week 24, n= 175 | 1 ± 20.87 |
| Alanine aminotransferase, Year 6, Week 48, n= 134 | -0.1 ± 13.25 |
| Alanine aminotransferase, Year 7, Week 24, n= 123 | -2.8 ± 13.96 |
| Alanine aminotransferase, Year 7, Week 48, n= 97 | -2.8 ± 15.06 |
| Alanine aminotransferase, Year 8, Week 24, n= 60 | -5.1 ± 12.06 |
| Alanine aminotransferase, Year 8, Week 48, n= 28 | -0.6 ± 11.39 |
| Alanine aminotransferase, Year 9, Week 24, n= 2 | 5 ± 4.24 |
| Alanine aminotransferase, Exit, n= 235 | -1.2 ± 13.77 |
| Alanine aminotransferase, 8 Week, Follow-Up, n= 10 | 0.1 ± 14.46 |
| Alkaline phosphatase, Year 1, Week 4, n= 251 | -0.8 ± 13.82 |
| Alkaline phosphatase, Year 1, Week 12, n= 248 | 0.4 ± 17.41 |
| Alkaline phosphatase, Year 1, Week 24, n= 246 | 0.3 ± 16.72 |
| Alkaline phosphatase, Year 1, Week 36, n= 238 | 1.2 ± 16.2 |
| Alkaline phosphatase, Year 1, Week 48, n= 250 | 3.3 ± 19.97 |
| Alkaline phosphatase, Year 2, Week 24, n= 248 | 4.9 ± 21.17 |
| Alkaline phosphatase, Year 2, Week 48, n= 233 | 5.8 ± 21.25 |
| Alkaline phosphatase, Year 3, Week 24, n= 218 | 5.4 ± 20.61 |
| Alkaline phosphatase, Year 3, Week 48, n= 209 | 3.1 ± 21.89 |
| Alkaline phosphatase, Year 4, Week 24, n= 207 | 6.5 ± 29.67 |
| Alkaline phosphatase, Year 4, Week 48, n= 194 | 6.2 ± 33.31 |
| Alkaline phosphatase, Year 5, Week 24, n= 184 | 7.8 ± 24.75 |
| Alkaline phosphatase, Year 5, Week 48, n= 178 | 6.7 ± 26.55 |
| Alkaline phosphatase, Year 6, Week 24, n= 175 | 7.5 ± 33.87 |
| Alkaline phosphatase, Year 6, Week 48, n= 134 | 6.6 ± 26.36 |
| Alkaline phosphatase, Year 7, Week 24, n= 123 | 5.5 ± 25 |
| Alkaline phosphatase, Year 7, Week 48, n= 97 | 5.2 ± 24.83 |
| Alkaline phosphatase, Year 8, Week 24, n= 60 | 2.3 ± 29.63 |
| Alkaline phosphatase, Year 8, Week 48, n= 28 | 0.3 ± 38.97 |
| Alkaline phosphatase, Year 9, Week 24, n= 2 | 19.5 ± 24.75 |
| Alkaline phosphatase, Exit, n= 235 | 4.6 ± 23.59 |
| Alkaline phosphatase, 8 Week, Follow-Up, n= 107 | 2.8 ± 26.98 |
| Aspartate aminotransferase ,Year 1, Week 4, n= 242 | 0.3 ± 11.18 |
| Aspartate aminotransferase ,Year 1,Week 12, n= 245 | -0.6 ± 9.37 |
| Aspartate aminotransferase ,Year 1,Week 24, n= 244 | -0.8 ± 8.14 |
| Aspartate aminotransferase,Year 1,Week 36,n=234 | -0.3 ± 11.29 |
| Aspartate aminotransferase ,Year 1,Week 48, n= 250 | -0.2 ± 10.67 |
| Aspartate aminotransferase , Year 2, Week 24,n=246 | 0.4 ± 10.97 |
| Aspartate aminotransferase , Year 2, Week 48,n=231 | 1 ± 12.24 |
| Aspartate aminotransferase , Year 3,Week 24,n=215 | 0.2 ± 9.49 |
| Aspartate aminotransferase ,Year 3,Week 48, n= 205 | 0.1 ± 14.63 |
| Aspartate aminotransferase , Year 4,Week 24, n=204 | 1.3 ± 14.74 |
| Aspartate aminotransferase , Year 4, Week 48,n=191 | 3.7 ± 32.99 |
| Aspartate aminotransferase , Year 5,Week 24, n=184 | 1.7 ± 16.27 |
| Aspartate aminotransferase , Year 5,Week 48, n=176 | 0.6 ± 15.15 |
| Aspartate aminotransferase , Year 6,Week 24,n= 172 | 2.4 ± 22.03 |
| Aspartate aminotransferase , Year 6,Week 48, n=134 | 1 ± 13.55 |
| Aspartate aminotransferase , Year 7,Week 24,n=121 | -0.6 ± 13.14 |
| Aspartate aminotransferase , Year 7, Week 48, n=97 | -1.1 ± 14.1 |
| Aspartate aminotransferase , Year 8, Week 24,n=60 | -2.7 ± 9.66 |
| Aspartate aminotransferase , Year 8, Week 48, n=28 | 0.1 ± 8.02 |
| Aspartate aminotransferase , Year 9, Week 24, n= 2 | 5 ± 4.24 |
| Aspartate aminotransferase , Exit, n= 235 | -0.4 ± 15.07 |
| Aspartate aminotransferase,8 Week,Follow-Up, n=107 | -0.7 ± 12.45 |
| Gamma glutamyl transferase, Year 1, Week 4, n= 251 | 0.5 ± 22.54 |
| Gamma glutamyl transferase, Year 1,Week 12, n= 248 | 0.5 ± 21.44 |
| Gamma glutamyl transferase, Year 1,Week 24, n= 246 | -1.3 ± 20.21 |
| Gamma glutamyl transferase, Year 1, Week 36, n=238 | -0.1 ± 18.64 |
| Gamma glutamyl transferase, Year 1, Week 48, n=250 | 2.2 ± 39.98 |
| Gamma glutamyl transferase, Year 2,Week 24, n= 248 | 1.2 ± 27.97 |
| Gamma glutamyl transferase, Year 2, Week 48,n= 233 | 1.9 ± 28.88 |
| Gamma glutamyl transferase, Year 3, Week 24, n=218 | 1.8 ± 20.1 |
| Gamma glutamyl transferase, Year 3, Week 48, n=209 | -2.4 ± 31.27 |
| Gamma glutamyl transferase, Year 4, Week 24, n=207 | 2.5 ± 45.58 |
| Gamma glutamyl transferase, Year 4, Week 48, n=194 | 1.5 ± 47.03 |
| Gamma glutamyl transferase, Year 5,Week 24, n= 184 | -0.4 ± 32.51 |
| Gamma glutamyl transferase, Year 5, Week 48, n=178 | 0.6 ± 40.11 |
| Gamma glutamyl transferase, Year 6, Week 24, n=175 | -3.3 ± 40.3 |
| Gamma glutamyl transferase, Year 6, Week 48, n=134 | -4.4 ± 37.08 |
| Gamma glutamyl transferase, Year 7, Week 24, n=123 | -7.2 ± 38.88 |
| Gamma glutamyl transferase, Year 7, Week 48, n= 97 | -8.8 ± 36.19 |
| Gamma glutamyl transferase, Year 8, Week 24, n= 60 | -12.9 ± 35.44 |
| Gamma glutamyl transferase, Year 8, Week 48, n= 28 | -6.9 ± 31.02 |
| Gamma glutamyl transferase, Year 9, Week 24, n= 2 | 2.5 ± 3.54 |
| Gamma glutamyl transferase, Exit, n= 235 | -2.2 ± 35.29 |
| Gamma glutamyl transferase, 8 Week,Follow-Up,n=107 | 2.1 ± 35.9 |
| Lactate dehydrogenase , Year 1, Week 4, n= 242 | 0.2 ± 26.46 |
| Lactate dehydrogenase , Year 1, Week 12, n= 245 | -2.4 ± 29.56 |
| Lactate dehydrogenase , Year 1, Week 24, n= 244 | -2.2 ± 37.57 |
| Lactate dehydrogenase , Year 1, Week 36, n= 234 | -2.8 ± 34.88 |
| Lactate dehydrogenase , Year 1, Week 48, n= 250 | -4.3 ± 35.5 |
| Lactate dehydrogenase , Year 2, Week 24, n= 246 | -4.8 ± 36.29 |
| Lactate dehydrogenase , Year 2, Week 48, n= 231 | -5.4 ± 40.42 |
| Lactate dehydrogenase , Year 3, Week 24, n= 215 | -8.1 ± 40.13 |
| Lactate dehydrogenase , Year 3, Week 48, n= 205 | -9.2 ± 47.95 |
| Lactate dehydrogenase , Year 4, Week 24, n= 204 | -7.7 ± 45.12 |
| Lactate dehydrogenase , Year 4, Week 48, n= 191 | -4.7 ± 53.17 |
| Lactate dehydrogenase , Year 5, Week 24, n= 184 | -5.5 ± 48.34 |
| Lactate dehydrogenase , Year 5, Week 48, n= 176 | -10.3 ± 49.81 |
| Lactate dehydrogenase , Year 6, Week 24, n= 172 | -2.7 ± 72.28 |
| Lactate dehydrogenase , Year 6, Week 48, n= 134 | -5.3 ± 55.64 |
| Lactate dehydrogenase , Year 7, Week 24, n= 121 | -7.9 ± 53.17 |
| Lactate dehydrogenase , Year 7, Week 48, n= 97 | -9.5 ± 57.15 |
| Lactate dehydrogenase , Year 8, Week 24, n= 60 | -11.2 ± 58.81 |
| Lactate dehydrogenase , Year 8, Week 48, n= 28 | -5.5 ± 81.78 |
| Lactate dehydrogenase , Year 9, Week 24, n= 2 | -9.5 ± 0.71 |
| Lactate dehydrogenase , Exit, n= 235 | -6.5 ± 56.73 |
| Lactate dehydrogenase , 8 Week, Follow-Up, n= 107 | -3.4 ± 52.66 |
Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Negative, Year 0-1, n=267 | 262 |
| Negative, Year 1-2, n=255 | 251 |
| Negative, Year 2-3, n=240 | 239 |
| Negative, Year 3-4, n=214 | 213 |
| Negative, Year 4-5, n=195 | 195 |
| Negative, Year 5-6, n=185 | 185 |
| Negative, Year 6-7, n=125 | 125 |
| Negative, Year 7 plus, n=63 | 63 |
| Transient positive, Year 0-1, n=267 | 5 |
| Transient positive, Year 1-2, n=255 | 4 |
| Transient positive, Year 2-3, n=240 | 0 |
| Transient positive, Year 3-4, n=214 | 1 |
| Transient positive, Year 4-5, n=195 | 0 |
| Transient positive, Year 5-6, n=185 | 0 |
| Transient positive, Year 6-7, n=125 | 0 |
| Transient positive, Year 7 plus, n=63 | 0 |
| Persistent positive, Year 0-1, n=267 | 0 |
| Persistent positive, Year 1-2, n=255 | 0 |
| Persistent positive, Year 2-3, n=240 | 0 |
| Persistent positive, Year 3-4, n=214 | 0 |
| Persistent positive, Year 4-5, n=195 | 0 |
| Persistent positive, Year 5-6, n=185 | 0 |
| Persistent positive, Year 6-7, n=125 | 0 |
| Persistent positive, Year 7 plus, n=63 | 0 |
| Unknown, Year 0-1, n=267 | 0 |
| Unknown, Year 1-2, n=255 | 0 |
| Unknown, Year 2-3, n=240 | 1 |
| Unknown, Year 3-4, n=214 | 0 |
| Unknown, Year 4-5, n=195 | 0 |
| Unknown, Year 5-6, n=185 | 0 |
| Unknown, Year 6-7, n=125 | 0 |
| Unknown, Year 7 plus, n=63 | 0 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Millimeters of mercury | Belimumab 10 mg/kg IV |
|---|---|
| DBP, Baseline, n= 268 | 74.3 ± 9.92 |
| DBP, Year 1 , Week 24, n= 255 | 74.5 ± 9.96 |
| DBP, Year 1 , Week 48, n= 255 | 73.5 ± 9.92 |
| DBP, Year 2 , Week 24, n= 251 | 74.5 ± 11.01 |
| DBP, Year 2 , Week 48, n= 236 | 73.5 ± 10.17 |
| DBP, Year 3 , Week 24, n= 223 | 73.6 ± 10.32 |
| DBP, Year 3 , Week 48, n= 214 | 73.4 ± 10.12 |
| DBP, Year 4 , Week 24, n= 214 | 74.4 ± 9.56 |
| DBP, Year 4 , Week 48, n= 199 | 75.2 ± 10.52 |
| DBP, Year 5 , Week 24, n= 187 | 74.3 ± 9.89 |
| DBP, Year 5 , Week 48, n= 185 | 73.4 ± 10.15 |
| DBP, Year 6 , Week 24, n= 178 | 74.1 ± 10.25 |
| DBP, Year 6 , Week 48, n= 138 | 73.9 ± 10.78 |
| DBP, Year 7 , Week 24, n= 124 | 75.2 ± 9.5 |
| DBP, Year 7 , Week 48, n= 98 | 73.1 ± 9.94 |
| DBP, Year 8 , Week 24, n= 60 | 73.4 ± 9.79 |
| DBP, Year 8 , Week 48, n= 29 | 73.6 ± 8.27 |
| DBP, Year 9 , Week 24, n= 2 | 90 ± 12.73 |
| DBP, Exit, n= 233 | 75.2 ± 9.77 |
| SBP, Baseline, n= 268 | 119.7 ± 15.75 |
| SBP, Year 1 , Week 24, n= 255 | 120 ± 16.14 |
| SBP, Year 1 , Week 48, n= 255 | 120.2 ± 14.66 |
| SBP, Year 2 , Week 24, n= 251 | 120.1 ± 16.49 |
| SBP, Year 2 , Week 48, n= 236 | 119.1 ± 15.22 |
| SBP, Year 3 , Week 24, n= 223 | 120.7 ± 16.23 |
| SBP, Year 3 , Week 48, n= 214 | 120.2 ± 14.44 |
| SBP, Year 4 , Week 24, n= 214 | 121.4 ± 14.61 |
| SBP, Year 4 , Week 48, n= 199 | 121.4 ± 15.03 |
| SBP, Year 5 , Week 24, n= 187 | 120.7 ± 14.92 |
| SBP, Year 5 , Week 48, n= 185 | 119.9 ± 15.29 |
| SBP, Year 6 , Week 24, n= 178 | 121.5 ± 15.29 |
| SBP, Year 6 , Week 48, n= 138 | 121.7 ± 15.86 |
| SBP, Year 7 , Week 24, n= 124 | 121.6 ± 14.73 |
| SBP, Year 7 , Week 48, n= 98 | 120.6 ± 14.19 |
| SBP, Year 8 , Week 24, n= 60 | 120.5 ± 14.65 |
| SBP, Year 8 , Week 48, n= 29 | 118.2 ± 11.73 |
| SBP, Year 9 , Week 24, n= 2 | 115.5 ± 6.36 |
| SBP, Exit, n= 233 | 123.3 ± 15.53 |
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage of Participants | Belimumab 10 mg/kg IV (Placebo) | Belimumab 10 mg/kg IV (Belimumab) |
|---|---|---|
| Year 0-1, n= 91, 177 | 7.7 | 23.2 |
| Year 1-2, n= 79, 177 | 3.8 | 20.3 |
| Year 2-3, n= 75, 168 | 2.7 | 8.3 |
| Year 3-4, n= 68, 150 | 4.4 | 6 |
| Year 4-5, n= 61, 139 | 4.9 | 9.4 |
| Year 5-6, n= 59, 132 | 5.1 | 9.1 |
| Year 6-7, n= 12, 118 | 8.3 | 11.9 |
| Year 7+, n= 0, 65 | 0 | 10.8 |
Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage of Participants | Belimumab 10 mg/kg IV (Placebo) | Belimumab 10 mg/kg IV (Belimumab) |
|---|---|---|
| Year 0-1, n= 6, 3 | 16.7 | 33.3 |
| Year 1-2, n= 5, 3 | 20 | 0 |
| Year 2-3, n= 3, 3 | 33.3 | 0 |
| Year 3-4, n= 2, 2 | 0 | 50 |
| Year 4-5, n= 2, 2 | 0 | 50 |
| Year 5-6, n= 2, 2 | 50 | 0 |
| Year 6-7, n= 1, 1 | 0 | 100 |
| Year 7+, n= 0, 0 | 0 | 0 |
Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (\<0.5 nanograms per milliliter \[ng/mL\]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n=268 | 8 |
| Year 1, Week 24, n= 252 | 14 |
| Year 1, Week 48, n= 255 | 16 |
| Year 2, Week 48, n= 237 | 19 |
| Year 3, Week 48, n= 224 | 17 |
| Year 4, Week 48, n= 208 | 26 |
| Year 5, Week 48, n= 190 | 19 |
| Year 6, Week 48, n= 150 | 21 |
| Year 7, Week 48, n= 112 | 21 |
| Year 8, Week 48, n= 59 | 5 |
| Exit, n= 235 | 29 |
| 8 Week Follow-Up, n= 106 | 10 |
The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:\>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage of Participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1 , Week 24, n= 229 | 41.9 |
| Year 1 , Week 48, n= 225 | 45.3 |
| Year 2 , Week 24, n= 227 | 49.3 |
| Year 2 , Week 48, n= 204 | 49 |
| Year 3 , Week 24, n= 211 | 51.2 |
| Year 3 , Week 48, n= 185 | 58.4 |
| Year 4 , Week 24, n= 188 | 56.9 |
| Year 4 , Week 48, n= 174 | 64.9 |
| Year 5 , Week 24, n= 168 | 66.7 |
| Year 5 , Week 48, n= 157 | 62.4 |
| Year 6 , Week 24, n= 164 | 69.5 |
| Year 6 , Week 48, n= 123 | 74 |
| Year 7 , Week 24, n= 119 | 75.6 |
| Year 7 , Week 48, n= 93 | 78.5 |
| Year 8 , Week 24, n= 63 | 66.7 |
| Year 8 , Week 48, n= 29 | 65.5 |
| Year 9 , Week 24, n= 2 | 0 |
Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA \>=30 International Units/milliliter \[IU/mL\]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| International units per milliliter | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n= 135 | 193 (34 to 201) |
| Year 1, Week 24, n= 128 | 127.5 (29 to 201) |
| Year 1, Week 48, n= 130 | 123 (29 to 201) |
| Year 2, Week 24, n= 126 | 93.5 (29 to 349) |
| Year 2, Week 48, n= 128 | 95 (5 to 2505) |
| Year 3, Week 24, n= 120 | 82.5 (5 to 1545) |
| Year 3, Week 48, n= 116 | 86.5 (5 to 556) |
| Year 4, Week 24, n= 112 | 87.5 (5 to 2305) |
| Year 4, Week 48, n= 100 | 76.5 (5 to 1873) |
| Year 5, Week 24, n= 98 | 60 (5 to 1188) |
| Year 5, Week 48, n= 96 | 47.5 (5 to 1765) |
| Year 6, Week 24, n= 87 | 47 (5 to 1863) |
| Year 6, Week 48, n= 66 | 50 (5 to 1018) |
| Year 7, Week 24, n= 63 | 35 (5 to 2648) |
| Year 7, Week 48, n= 48 | 32 (5 to 736) |
| Year 8, Week 24, n= 35 | 29 (5 to 521) |
| Year 8, Week 48, n= 16 | 50.5 (5 to 439) |
| Year 9, Week 24, n= 1 | 45 (45 to 45) |
| Exit, n= 120 | 37 (5 to 1608) |
Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage change | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 24, n= 128 | -9.77 (-75.6 to 54.6) |
| Year 1, Week 48, n= 130 | -15.58 (-84.2 to 183.1) |
| Year 2, Week 24, n= 126 | -27.5 (-84.7 to 181.7) |
| Year 2, Week 48, n= 128 | -30.12 (-90.6 to 1253.6) |
| Year 3, Week 24, n= 120 | -34.22 (-90.6 to 668.7) |
| Year 3, Week 48, n= 116 | -34.92 (-90.6 to 176.6) |
| Year 4, Week 24, n= 112 | -38.58 (-90.6 to 1046.8) |
| Year 4, Week 48, n= 100 | -54.46 (-96 to 831.8) |
| Year 5, Week 24, n= 98 | -54.39 (-96.5 to 491) |
| Year 5, Week 48, n= 96 | -64.43 (-97.5 to 778.1) |
| Year 6, Week 24, n= 87 | -64.04 (-97.5 to 826.9) |
| Year 6, Week 48, n= 66 | -64.91 (-97.5 to 406.5) |
| Year 7, Week 24, n= 63 | -74.74 (-97.5 to 1217.4) |
| Year 7, Week 48, n= 48 | -78.15 (-97.5 to 557.1) |
| Year 8, Week 24, n= 35 | -79.1 (-97.5 to 365.2) |
| Year 8, Week 48, n= 16 | -72.38 (-97.5 to 292) |
| Year 9, Week 24, n= 1 | -77.6 (-77.6 to -77.6) |
| Exit, n= 120 | -66.67 (-97.5 to 700) |
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligram per deciliter (mg/dL) and C4 \<16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Milligrams per deciliter | Belimumab 10 mg/kg IV |
|---|---|
| C3, Baseline, n= 86 | 76 (40 to 89) |
| C3, Year 1, Week 24, n= 83 | 80 (43 to 160) |
| C3, Year 1, Week 48, n= 83 | 86 (38 to 144) |
| C3, Year 2, Week 24, n= 81 | 85 (46 to 157) |
| C3, Year 2, Week 48, n= 80 | 88.5 (36 to 137) |
| C3, Year 3, Week 24, n= 74 | 90.5 (55 to 133) |
| C3, Year 3, Week 48, n= 73 | 93 (51 to 139) |
| C3, Year 4, Week 24, n= 72 | 94 (47 to 150) |
| C3, Year 4, Week 48, n= 66 | 95 (58 to 137) |
| C3, Year 5, Week 24, n= 63 | 99 (64 to 193) |
| C3, Year 5, Week 48, n= 61 | 97 (56 to 172) |
| C3, Year 6, Week 24, n= 55 | 99 (54 to 161) |
| C3, Year 6, Week 48, n= 37 | 103 (47 to 158) |
| C3, Year 7, Week 24, n= 41 | 103 (50 to 147) |
| C3, Year 7, Week 48, n= 32 | 110 (51 to 173) |
| C3, Year 8, Week 24, n= 20 | 110.5 (76 to 177) |
| C3, Year 8, Week 48, n= 9 | 104 (79 to 158) |
| C3, Exit, n= 74 | 103 (56 to 173) |
| C4, Baseline, n=98 | 10 (3 to 15) |
| C4, Year 1, Week 24, n=95 | 13 (3 to 25) |
| C4, Year 1, Week 48, n=93 | 15 (4 to 28) |
| C4, Year 2, Week 24, n=93 | 15 (3 to 29) |
| C4, Year 2, Week 48, n=94 | 16 (4 to 37) |
| C4, Year 3, Week 24, n=84 | 15.5 (4 to 31) |
| C4, Year 3, Week 48, n=83 | 16 (3 to 35) |
| C4, Year 4, Week 24, n=81 | 16 (3 to 38) |
| C4, Year 4, Week 48, n=71 | 17 (4 to 26) |
| C4, Year 5, Week 24, n=70 | 18 (4 to 40) |
| C4, Year 5, Week 48, n=70 | 18 (3 to 39) |
| C4, Year 6, Week 24, n=62 | 18 (5 to 36) |
| C4, Year 6, Week 48, n=45 | 18 (5 to 29) |
| C4, Year 7, Week 24, n=49 | 19 (6 to 34) |
| C4, Year 7, Week 48, n=35 | 19 (6 to 34) |
| C4, Year 8, Week 24, n=24 | 20.5 (10 to 35) |
| C4, Year 8, Week 48, n=12 | 18 (7 to 36) |
| C4, Year 9, Week 24, n=1 | 22 (22 to 22) |
| C4, Exit, n=85 | 18 (4 to 41) |
Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 \<90 milligrams per decilitre (mg/dL) and C4 \<16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percent Change | Belimumab 10 mg/kg IV |
|---|---|
| C3, Year 1, Week 24, n= 83 | 10.91 (-33 to 281) |
| C3, Year 1, Week 48, n= 83 | 17.86 (-45.3 to 104.8) |
| C3, Year 2, Week 24, n= 81 | 18.64 (-23.3 to 192.9) |
| C3, Year 2, Week 48, n= 80 | 16.71 (-37.9 to 163.3) |
| C3, Year 3, Week 24, n= 74 | 24.26 (-17.3 to 161.2) |
| C3, Year 3, Week 48, n= 73 | 22.73 (-34.6 to 163.3) |
| C3, Year 4, Week 24, n= 72 | 32.43 (-32.9 to 206.1) |
| C3, Year 4, Week 48, n= 66 | 30.63 (-27.5 to 177.6) |
| C3, Year 5, Week 24, n= 63 | 33.93 (-24.7 to 175.7) |
| C3, Year 5, Week 48, n= 61 | 34.29 (-17.9 to 173.5) |
| C3, Year 6, Week 24, n= 55 | 35.71 (-18 to 159.7) |
| C3, Year 6, Week 48, n= 37 | 34.57 (-32.9 to 166.7) |
| C3, Year 7, Week 24, n= 41 | 36.11 (-34.2 to 137.1) |
| C3, Year 7, Week 48, n= 32 | 42.04 (-36.3 to 179) |
| C3, Year 8, Week 24, n= 20 | 36.97 (7.7 to 185.5) |
| C3, Year 8, Week 48, n= 9 | 30.16 (5 to 163.3) |
| C3, Exit, n= 74 | 39.05 (-25.6 to 195.2) |
| C4, Year 1, Week 24, n=95 | 30.77 (-53.3 to 275) |
| C4, Year 1, Week 48, n=93 | 40 (-40 to 200) |
| C4, Year 2, Week 24, n=93 | 42.86 (-57.1 to 350) |
| C4, Year 2, Week 48, n=94 | 47.73 (-33.3 to 270) |
| C4, Year 3, Week 24, n=84 | 50 (-20 to 266.7) |
| C4, Year 3, Week 48, n=83 | 46.15 (-40 to 250) |
| C4, Year 4, Week 24, n=81 | 57.14 (-70 to 450) |
| C4, Year 4, Week 48, n=71 | 58.33 (-42.9 to 433.3) |
| C4, Year 5, Week 24, n=70 | 70.33 (-30 to 500) |
| C4, Year 5, Week 48, n=70 | 65.15 (-40 to 566.7) |
| C4, Year 6, Week 24, n=62 | 71.36 (-10 to 800) |
| C4, Year 6, Week 48, n=45 | 57.14 (-40 to 600) |
| C4, Year 7, Week 24, n=49 | 63.64 (-40 to 700) |
| C4, Year 7, Week 48, n=35 | 62.5 (-14.3 to 900) |
| C4, Year 8, Week 24, n=24 | 78.97 (0 to 900) |
| C4, Year 8, Week 48, n=12 | 69.74 (-30 to 1100) |
| C4, Year 9, Week 24, n=1 | 100 (100 to 100) |
| C4, Exit, n=85 | 75 (-53.8 to 1066.7) |
Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage of Participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 24, n= 80 | 2.5 |
| Year 1, Week 48, n= 81 | 21 |
| Year 2, Week 24, n= 78 | 38.5 |
| Year 2, Week 48, n= 76 | 40.8 |
| Year 3, Week 24, n= 64 | 50 |
| Year 3, Week 48, n= 63 | 41.3 |
| Year 4, Week 24, n= 65 | 43.1 |
| Year 4, Week 48, n= 62 | 37.1 |
| Year 5, Week 24, n= 57 | 33.3 |
| Year 5, Week 48, n= 57 | 38.6 |
| Year 6, Week 24, n= 55 | 34.5 |
| Year 6, Week 48, n= 47 | 42.6 |
| Year 7, Week 24, n= 42 | 38.1 |
| Year 7, Week 48, n= 38 | 39.5 |
| Year 8, Week 24, n= 24 | 50 |
| Year 8, Week 48, n= 12 | 58.3 |
| Year 9, Week 24, n= 2 | 100 |
Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with \>= 50% reduction in proteinuria among participants with Baseline proteinuria \>0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage of Participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 24, n=34 | 41.2 |
| Year 1, Week 48, n=33 | 63.6 |
| Year 2, Week 24, n=33 | 60.6 |
| Year 2, Week 48, n=30 | 53.3 |
| Year 3, Week 24, n=31 | 74.2 |
| Year 3, Week 48, n=28 | 67.9 |
| Year 4, Week 24, n=25 | 88 |
| Year 4, Week 48, n=23 | 73.9 |
| Year 5, Week 24, n=23 | 73.9 |
| Year 5, Week 48, n=22 | 86.4 |
| Year 6, Week 24, n=22 | 77.3 |
| Year 6, Week 48, n=17 | 76.5 |
| Year 7, Week 24, n=14 | 78.6 |
| Year 7, Week 48, n=7 | 71.4 |
| Year 8, Week 24, n=4 | 75 |
| Year 8, Week 48, n=1 | 100 |
| Year 9, Week 24, n=28 | 64.3 |
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Cell count | Belimumab 10 mg/kg IV |
|---|---|
| CD20+, Baseline, n= 262 | 112.5 (2 to 807) |
| CD20+, Yr 1, Wk 24, n= 251 | 68 (2 to 433) |
| CD20+, Yr 1, Wk 48, n= 242 | 50 (2 to 407) |
| CD20+, Yr 2, Wk 24, n= 238 | 37.5 (5 to 278) |
| CD20+, Yr 2, Wk 48, n= 224 | 34 (5 to 1528) |
| CD20+, Yr 3, Wk 24, n= 212 | 31 (5 to 293) |
| CD20+, Yr 3, Wk 48, n= 202 | 26 (5 to 500) |
| CD20+, Yr 4, Wk 24, n= 196 | 27 (3 to 355) |
| CD20+, Yr 4, Wk 48, n= 181 | 23 (5 to 238) |
| CD20+, Yr 5, Wk 24, n= 172 | 22 (1 to 141) |
| CD20+, Yr 5, Wk 48, n= 166 | 18.5 (5 to 248) |
| CD20+, Yr 6, Wk 24, n= 159 | 21 (4 to 397) |
| CD20+, Yr 6, Wk 48, n= 114 | 20 (4 to 113) |
| CD20+, Yr 7, Wk 24, n= 111 | 20 (4 to 158) |
| CD20+, Yr 7, Wk 48, n= 87 | 21 (5 to 120) |
| CD20+, Yr 8, Wk 24, n= 54 | 17 (5 to 91) |
| CD20+, Yr 8, Wk 48, n= 28 | 15.5 (5 to 57) |
| CD20+, Yr 9, Wk 24, n= 2 | 7.5 (7 to 8) |
| CD20+, Exit, n= 207 | 22 (3 to 364) |
| CD19+/27BRIGHT/38BRIGHT SLE, Baseline, n= 262 | 17 (0 to 600) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 24, n= 251 | 13 (0 to 452) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 48, n= 247 | 12 (0 to 177) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 24, n= 246 | 14 (0 to 204) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 48, n= 233 | 13 (0 to 345) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 24, n= 218 | 12 (0 to 216) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 48, n= 212 | 12 (0 to 331) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 24, n= 211 | 14 (0 to 407) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 48, n= 194 | 14 (0 to 442) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 24, n= 189 | 11 (0 to 414) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 48, n= 181 | 11 (0 to 591) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 24, n= 174 | 10.5 (0 to 443) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 48, n= 133 | 10 (0 to 248) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 24, n= 122 | 9 (0 to 381) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 48, n= 97 | 8 (0 to 156) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 24, n= 60 | 6.5 (0 to 755) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 48, n= 29 | 5 (0 to 39) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 9, Wk 24, n= 2 | 17.5 (6 to 29) |
| CD19+/27BRIGHT/38BRIGHT SLE, Exit, n= 232 | 9 (0 to 555) |
| CD19+20-27hi+ SLPC, Baseline, n= 258 | 16 (0 to 585) |
| CD19+20-27hi+ SLPC, Yr 1, Wk 24, n= 247 | 13 (0 to 443) |
| CD19+20-27hi+ SLPC, Yr 1, Wk 48, n= 244 | 11 (0 to 145) |
| CD19+20-27hi+ SLPC, Yr 2, Wk 24, n= 244 | 13 (0 to 289) |
| CD19+20-27hi+ SLPC, Yr 2, Wk 48, n= 233 | 13 (0 to 316) |
| CD19+20-27hi+ SLPC, Yr 3, Wk 24, n= 218 | 12 (0 to 210) |
| CD19+20-27hi+ SLPC, Yr 3, Wk 48, n= 211 | 12 (0 to 324) |
| CD19+20-27hi+ SLPC, Yr 4, Wk 24, n= 210 | 13 (0 to 364) |
| CD19+20-27hi+ SLPC, Yr 4, Wk 48, n= 193 | 12 (0 to 452) |
| CD19+20-27hi+ SLPC, Yr 5, Wk 24, n= 188 | 10.5 (0 to 377) |
| CD19+20-27hi+ SLPC, Yr 5, Wk 48, n= 181 | 10 (0 to 597) |
| CD19+20-27hi+ SLPC, Yr 6, Wk 24, n= 174 | 9 (0 to 400) |
| CD19+20-27hi+ SLPC, Yr 6, Wk 48, n= 133 | 8 (0 to 227) |
| CD19+20-27hi+ SLPC, Yr 7, Wk 24, n= 122 | 9 (0 to 328) |
| CD19+20-27hi+ SLPC, Yr 7, Wk 48, n= 97 | 9 (0 to 156) |
| CD19+20-27hi+ SLPC, Yr 8, Wk 24, n= 60 | 9 (0 to 754) |
| CD19+20-27hi+ SLPC, Yr 8, Wk 48, n= 29 | 4 (0 to 42) |
| CD19+20-27hi+ SLPC, Yr 9, Wk 24, n= 2 | 16 (4 to 28) |
| CD19+20-27hi+ SLPC, Exit, n= 233 | 9 (0 to 603) |
| CD20+/138+ plasmacytoid, Baseline, n= 261 | 95 (0 to 4274) |
| CD20+/138+ plasmacytoid, Yr 1, Wk 24, n= 251 | 64 (1 to 1613) |
| CD20+/138+ plasmacytoid, Yr 1, Wk 48, n= 247 | 37 (2 to 962) |
| CD20+/138+ plasmacytoid, Yr 2, Wk 24, n= 246 | 32.5 (0 to 221) |
| CD20+/138+ plasmacytoid, Yr 2, Wk 48, n= 233 | 27 (1 to 249) |
| CD20+/138+ plasmacytoid, Yr 3, Wk 24, n= 218 | 24 (0 to 322) |
| CD20+/138+ plasmacytoid, Yr 3, Wk 48, n= 212 | 12 (0 to 220) |
| CD20+/138+ plasmacytoid, Yr 4, Wk 24, n= 211 | 8 (0 to 128) |
| CD20+/138+ plasmacytoid, Yr 4, Wk 48, n= 194 | 5 (0 to 246) |
| CD20+/138+ plasmacytoid, Yr 5, Wk 24, n= 189 | 4 (0 to 136) |
| CD20+/138+ plasmacytoid, Yr 5, Wk 48, n= 181 | 3 (0 to 102) |
| CD20+/138+ plasmacytoid, Yr 6, Wk 24, n= 174 | 3 (0 to 38) |
| CD20+/138+ plasmacytoid, Yr 6, Wk 48, n= 133 | 3 (0 to 25) |
| CD20+/138+ plasmacytoid, Yr 7, Wk 24, n= 122 | 2 (0 to 70) |
| CD20+/138+ plasmacytoid, Yr 7, Wk 48, n= 97 | 2 (0 to 23) |
| CD20+/138+ plasmacytoid, Yr 8, Wk 24, n= 60 | 2 (0 to 18) |
| CD20+/138+ plasmacytoid, Yr 8, Wk 48, n= 29 | 1 (0 to 16) |
| CD20+/138+ plasmacytoid, Yr 9, Wk 24, n= 2 | 1 (0 to 2) |
| CD20+/138+ plasmacytoid, Exit, n= 232 | 3 (0 to 231) |
| CD20+/27+Memory, Baseline, n= 262 | 17 (0 to 177) |
| CD20+/27+Memory, Yr 1, Wk 24, n= 251 | 30 (1 to 279) |
| CD20+/27+Memory, Yr 1, Wk 48, n= 242 | 23 (0 to 275) |
| CD20+/27+Memory, Yr 2, Wk 24, n= 238 | 17 (1 to 181) |
| CD20+/27+Memory, Yr 2, Wk 48, n= 224 | 16 (1 to 686) |
| CD20+/27+Memory, Yr 3, Wk 24, n= 212 | 13 (0 to 88) |
| CD20+/27+Memory, Yr 3, Wk 48, n= 202 | 11 (1 to 342) |
| CD20+/27+Memory, Yr 4, Wk 24, n= 196 | 10.5 (1 to 276) |
| CD20+/27+Memory, Yr 4, Wk 48, n= 181 | 9 (1 to 196) |
| CD20+/27+Memory, Yr 5, Wk 24, n= 172 | 8.5 (1 to 76) |
| CD20+/27+Memory, Yr 5, Wk 48, n= 166 | 7 (1 to 166) |
| CD20+/27+Memory, Yr 6,Wk 24,n=158 | 7 (1 to 73) |
| CD20+/27+Memory, Yr 6, Wk 48, n= 114 | 6 (1 to 46) |
| CD20+/27+Memory, Yr 7, Wk 24, n= 111 | 6 (1 to 91) |
| CD20+/27+Memory, Yr 7, Wk 48, n= 87 | 6 (1 to 81) |
| CD20+/27+Memory, Yr 8, Wk 24, n= 54 | 5 (1 to 34) |
| CD20+/27+Memory, Yr 8, Wk 48, n= 28 | 6 (1 to 32) |
| CD20+/27+Memory, Yr 9, Wk 24, n= 2 | 2 (1 to 3) |
| CD20+/27+Memory, Exit, n= 207 | 8 (0 to 167) |
| CD20+/27-naive, Baseline, n= 262 | 88 (1 to 717) |
| CD20+/27-naive, Yr 1, Wk 24, n= 251 | 36 (1 to 371) |
| CD20+/27-naive, Yr 1, Wk 48, n= 242 | 25 (1 to 209) |
| CD20+/27-naive, Yr 2, Wk 24, n= 238 | 21 (2 to 176) |
| CD20+/27-naive, Yr 2, Wk 48, n= 224 | 17 (1 to 826) |
| CD20+/27-naive, Yr 3, Wk 24, n= 212 | 16 (1 to 243) |
| CD20+/27-naive, Yr 3, Wk 48, n= 202 | 14 (1 to 163) |
| CD20+/27-naive, Yr 4, Wk 24, n= 196 | 15 (2 to 140) |
| CD20+/27-naive, Yr 4, Wk 48, n= 181 | 12 (1 to 152) |
| CD20+/27-naive, Yr 5, Wk 24, n= 172 | 12.5 (0 to 127) |
| CD20+/27-naive, Yr 5, Wk 48, n= 166 | 11 (2 to 176) |
| CD20+/27-naive, Yr 6, Wk 24, n= 159 | 12 (0 to 67) |
| CD20+/27-naive, Yr 6, Wk 48, n= 114 | 13 (1 to 68) |
| CD20+/27-naive, Yr 7, Wk 24, n= 111 | 13 (1 to 69) |
| CD20+/27-naive, Yr 7, Wk 48, n= 87 | 12 (2 to 59) |
| CD20+/27-naive, Yr 8, Wk 24, n= 54 | 11.5 (2 to 62) |
| CD20+/27-naive, Yr 8, Wk 48, n= 28 | 12 (2 to 54) |
| CD20+/27-naive, Yr 9, Wk 24, n= 2 | 5.5 (4 to 7) |
| CD20+/27-naive, Exit, n= 207 | 13 (1 to 313) |
| CD20+/69+activated, Baseline, n= 257 | 190 (11 to 2492) |
| CD20+/69+activated, Yr 1, Wk 24, n= 247 | 131 (7 to 1503) |
| CD20+/69+activated, Yr 1, Wk 48, n= 244 | 82 (1 to 561) |
| CD20+/69+activated, Yr 2, Wk 24, n= 244 | 74 (0 to 916) |
| CD20+/69+activated, Yr 2, Wk 48, n= 233 | 56 (0 to 472) |
| CD20+/69+activated, Yr 3, Wk 24, n= 218 | 31 (0 to 242) |
| CD20+/69+activated, Yr 3, Wk 48, n= 211 | 22 (0 to 233) |
| CD20+/69+activated, Yr 4, Wk 24, n= 210 | 13 (0 to 687) |
| CD20+/69+activated, Yr 4, Wk 48, n= 193 | 8 (0 to 288) |
| CD20+/69+activated, Yr 5, Wk 24, n= 188 | 6 (0 to 147) |
| CD20+/69+activated, Yr 5, Wk 48, n= 181 | 4 (0 to 61) |
| CD20+/69+activated, Yr 6, Wk 24, n= 174 | 4 (0 to 40) |
| CD20+/69+activated, Yr 6, Wk 48, n= 133 | 3 (0 to 56) |
| CD20+/69+activated, Yr 7, Wk 24, n= 122 | 3 (0 to 43) |
| CD20+/69+activated, Yr 7, Wk 48, n= 97 | 2 (0 to 29) |
| CD20+/69+activated, Yr 8, Wk 24, n= 60 | 1.5 (0 to 21) |
| CD20+/69+activated, Yr 8, Wk 48, n= 29 | 1 (0 to 10) |
| CD20+/69+activated, Yr 9, Wk 24, n= 2 | 0.5 (0 to 1) |
| CD20+/69+activated, Exit, n= 233 | 2 (0 to 457) |
| CD20-/138+plasma cells, Baseline, n= 261 | 41 (1 to 870) |
| CD20-/138+plasma cells, Yr 1, Wk 24, n= 251 | 31 (0 to 393) |
| CD20-/138+plasma cells, Yr 1, Wk 48, n= 247 | 24 (0 to 255) |
| CD20-/138+plasma cells, Yr 2, Wk 24, n= 246 | 23 (0 to 446) |
| CD20-/138+plasma cells, Yr 2, Wk 48, n= 233 | 20 (0 to 1513) |
| CD20-/138+plasma cells, Yr 3, Wk 24, n= 218 | 19 (0 to 312) |
| CD20-/138+plasma cells, Yr 3, Wk 48, n= 212 | 16 (0 to 225) |
| CD20-/138+plasma cells, Yr 4, Wk 24, n= 211 | 14 (0 to 337) |
| CD20-/138+plasma cells, Yr 4, Wk 48, n= 194 | 7.5 (0 to 214) |
| CD20-/138+plasma cells, Yr 5, Wk 24, n= 189 | 6 (0 to 135) |
| CD20-/138+plasma cells, Yr 5, Wk 48, n= 181 | 6 (0 to 75) |
| CD20-/138+plasma cells, Yr 6, Wk 24, n= 174 | 4 (0 to 50) |
| CD20-/138+plasma cells, Yr 6, Wk 48, n= 133 | 4 (0 to 64) |
| CD20-/138+plasma cells, Yr 7, Wk 24, n= 122 | 4.5 (0 to 84) |
| CD20-/138+plasma cells, Yr 7, Wk 48, n= 97 | 4 (0 to 47) |
| CD20-/138+plasma cells, Yr 8, Wk 24, n= 60 | 3 (0 to 75) |
| CD20-/138+plasma cells, Yr 8, Wk 48, n= 29 | 2 (0 to 28) |
| CD20-/138+plasma cells, Yr 9, Wk 24, n= 2 | 8 (2 to 14) |
| CD20-/138+plasma cells, Exit, n= 232 | 5 (0 to 221) |
| Total CD19+ B-cells (CD19+), Baseline, n= 265 | 114 (4 to 815) |
| Total CD19+ B-cells (CD19+), Yr 1, Wk 24, n= 253 | 69 (4 to 437) |
| Total CD19+ B-cells (CD19+), Yr 1, Wk 48, n= 254 | 49 (4 to 411) |
| Total CD19+ B-cells (CD19+), Yr 2, Wk 24, n= 247 | 37 (4 to 281) |
| Total CD19+ B-cells (CD19+), Yr 2, Wk 48, n= 234 | 34 (4 to 1559) |
| Total CD19+ B-cells (CD19+), Yr 3, Wk 24, n= 220 | 30 (4 to 296) |
| Total CD19+ B-cells (CD19+), Yr 3, Wk 48, n= 212 | 26 (4 to 510) |
| Total CD19+ B-cells (CD19+), Yr 4, Wk 24, n= 211 | 25 (4 to 359) |
| Total CD19+ B-cells (CD19+), Yr 4, Wk 48, n= 195 | 22 (4 to 245) |
| Total CD19+ B-cells (CD19+), Yr 5, Wk 24, n= 190 | 19 (4 to 144) |
| Total CD19+ B-cells (CD19+), Yr 5, Wk 48, n= 182 | 18 (4 to 301) |
| Total CD19+ B-cells (CD19+), Yr 6, Wk 24, n= 175 | 19 (4 to 117) |
| Total CD19+ B-cells (CD19+), Yr 6, Wk 48, n= 132 | 17.5 (4 to 114) |
| Total CD19+ B-cells (CD19+), Yr 7, Wk 24, n= 122 | 18.5 (4 to 160) |
| Total CD19+ B-cells (CD19+), Yr 7, Wk 48, n= 97 | 19 (4 to 121) |
| Total CD19+ B-cells (CD19+), Yr 8, Wk 24, n= 60 | 16.5 (4 to 92) |
| Total CD19+ B-cells (CD19+), Yr 8, Wk 48, n= 29 | 15 (4 to 58) |
| Total CD19+ B-cells (CD19+), Yr 9, Wk 24, n= 2 | 7.5 (7 to 8) |
| Total CD19+ B-cells (CD19+), Exit, n= 234 | 20 (4 to 368) |
B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x (\[Post-Dose Visit Value - Baseline\] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Percentage change | Belimumab 10 mg/kg IV |
|---|---|
| CD20+, Yr 1, Wk 24, n= 245 | -31.82 (-91.9 to 394.1) |
| CD20+, Yr 1, Wk 48, n= 237 | -51.61 (-94.7 to 216.7) |
| CD20+, Yr 2, Wk 24, n= 233 | -61.76 (-95.4 to 250) |
| CD20+, Yr 2, Wk 48, n= 218 | -66.21 (-96.3 to 1616.9) |
| CD20+, Yr 3, Wk 24, n= 206 | -69.68 (-96.2 to 250) |
| CD20+, Yr 3, Wk 48, n= 196 | -72.77 (-97.3 to 270.6) |
| CD20+, Yr 4, Wk 24, n= 191 | -75.16 (-96.8 to 82.4) |
| CD20+, Yr 4, Wk 48, n= 175 | -78.33 (-97.6 to 561.1) |
| CD20+, Yr 5, Wk 24, n= 166 | -80.26 (-97.6 to 156.3) |
| CD20+, Yr 5, Wk 48, n= 161 | -81.06 (-98.1 to 93.8) |
| CD20+, Yr 6, Wk 24, n= 154 | -81.87 (-98.1 to 2381.3) |
| CD20+, Yr 6, Wk 48, n= 109 | -82.94 (-96.7 to 102.9) |
| CD20+, Yr 7, Wk 24, n= 107 | -83.22 (-97.6 to 188.9) |
| CD20+, Yr 7, Wk 48, n= 82 | -80.96 (-97.3 to 172.2) |
| CD20+, Yr 8, Wk 24, n= 52 | -78.94 (-96.9 to 244.4) |
| CD20+, Yr 8, Wk 48, n= 27 | -85.29 (-95.5 to 105.9) |
| CD20+, Yr 9, Wk 24, n= 2 | -63.65 (-84.4 to -42.9) |
| CD20+, Exit, n= 203 | -80.6 (-98.2 to 225) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 24, n= 243 | -16.13 (-100 to 4500) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 1, Wk 48, n= 240 | -38.74 (-100 to 4800) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 24, n= 239 | -25 (-100 to 2200) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 2, Wk 48, n= 225 | -26.23 (-100 to 33100) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 24, n= 210 | -33.97 (-100 to 6800) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 3, Wk 48, n= 204 | -37.98 (-100 to 4900) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 24, n= 204 | -19.52 (-100 to 2787.5) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 4, Wk 48, n= 187 | -16.67 (-100 to 5500) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 24, n= 182 | -33.33 (-100 to 4900) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 5, Wk 48, n= 174 | -37.46 (-100 to 10000) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 24, n= 167 | -44.44 (-100 to 11100) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 6, Wk 48, n= 126 | -50 (-100 to 24700) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 24, n= 117 | -50 (-100 to 29300) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 7, Wk 48, n= 92 | -70.76 (-100 to 2100) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 24, n= 57 | -71.43 (-100 to 1787.5) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 8, Wk 48, n= 28 | -85 (-100 to 100) |
| CD19+/27BRIGHT/38BRIGHT SLE, Yr 9, Wk 24, n= 2 | 210.98 (-78 to 500) |
| CD19+/27BRIGHT/38BRIGHT SLE, Exit, n= 226 | -50 (-100 to 6100) |
| CD19+20-27hi+ SLPC, Yr 1, Wk 24, n= 238 | -32.29 (-100 to 4330) |
| CD19+20-27hi+ SLPC, Yr 1, Wk 48, n= 235 | -40 (-100 to 1400) |
| CD19+20-27hi+ SLPC, Yr 2, Wk 24, n= 234 | -27.05 (-100 to 2000) |
| CD19+20-27hi+ SLPC, Yr 2, Wk 48, n= 221 | -30 (-100 to 4385.7) |
| CD19+20-27hi+ SLPC, Yr 3, Wk 24, n= 207 | -37.5 (-100 to 1300) |
| CD19+20-27hi+ SLPC, Yr 3, Wk 48, n= 199 | -40.54 (-100 to 6600) |
| CD19+20-27hi+ SLPC, Yr 4, Wk 24, n= 199 | -29.41 (-100 to 1900) |
| CD19+20-27hi+ SLPC, Yr 4, Wk 48, n= 184 | -29.29 (-100 to 1250) |
| CD19+20-27hi+ SLPC, Yr 5, Wk 24, n= 178 | -44.6 (-100 to 1400) |
| CD19+20-27hi+ SLPC, Yr 5, Wk 48, n= 171 | -45.65 (-100 to 1328.6) |
| CD19+20-27hi+ SLPC, Yr 6, Wk 24, n= 165 | -62.5 (-100 to 3400) |
| CD19+20-27hi+ SLPC, Yr 6, Wk 48, n= 123 | -62.5 (-100 to 3400) |
| CD19+20-27hi+ SLPC, Yr 7, Wk 24, n= 114 | -47.5 (-100 to 4128.6) |
| CD19+20-27hi+ SLPC, Yr 7, Wk 48, n= 89 | -58.33 (-100 to 2900) |
| CD19+20-27hi+ SLPC, Yr 8, Wk 24, n= 55 | -62.07 (-100 to 1884.2) |
| CD19+20-27hi+ SLPC, Yr 8, Wk 48, n= 27 | -84.62 (-100 to 10.5) |
| CD19+20-27hi+ SLPC, Yr 9, Wk 24, n= 1 | -79.4 (-79.4 to -79.4) |
| CD19+20-27hi+ SLPC, Exit, n= 224 | -51.42 (-100 to 2000) |
| CD20+/138+ plasmacytoid, Yr 1, Wk 24, n= 243 | -32.49 (-97.4 to 6352) |
| CD20+/138+ plasmacytoid, Yr 1, Wk 48, n= 240 | -61.11 (-99 to 923.4) |
| CD20+/138+ plasmacytoid, Yr 2, Wk 24, n= 239 | -66 (-100 to 2233.3) |
| CD20+/138+ plasmacytoid, Yr 2, Wk 48, n= 225 | -70.64 (-99.2 to 422.2) |
| CD20+/138+ plasmacytoid, Yr 3, Wk 24, n= 211 | -78.57 (-100 to 644.4) |
| CD20+/138+ plasmacytoid, Yr 3, Wk 48, n= 204 | -88.89 (-100 to 863.6) |
| CD20+/138+ plasmacytoid, Yr 4, Wk 24, n= 204 | -93.14 (-100 to 156) |
| CD20+/138+ plasmacytoid, Yr 4, Wk 48, n= 186 | -94.17 (-100 to 35) |
| CD20+/138+ plasmacytoid, Yr 5, Wk 24, n= 181 | -96.25 (-100 to 33.3) |
| CD20+/138+ plasmacytoid, Yr 5, Wk 48, n= 174 | -96.75 (-100 to -21.2) |
| CD20+/138+ plasmacytoid, Yr 6, Wk 24, n= 167 | -96.53 (-100 to -9.1) |
| CD20+/138+ plasmacytoid, Yr 6, Wk 48, n= 126 | -97.96 (-100 to -36.4) |
| CD20+/138+ plasmacytoid, Yr 7, Wk 24, n= 117 | -98 (-100 to -33.3) |
| CD20+/138+ plasmacytoid, Yr 7, Wk 48, n= 91 | -98.46 (-100 to -40) |
| CD20+/138+ plasmacytoid, Yr 8, Wk 24, n= 57 | -98.64 (-100 to -70) |
| CD20+/138+ plasmacytoid, Yr 8, Wk 48, n= 28 | -98.68 (-100 to -92.9) |
| CD20+/138+ plasmacytoid, Yr 9, Wk 24, n= 2 | -96.15 (-100 to -92.3) |
| CD20+/138+ plasmacytoid, Exit, n= 225 | -96.83 (-100 to 610.7) |
| CD20+/27+Memory, Yr 1, Wk 24, n= 244 | 87.65 (-97.1 to 1420) |
| CD20+/27+Memory, Yr 1, Wk 48, n= 237 | 42.86 (-100 to 800) |
| CD20+/27+Memory, Yr 2, Wk 24, n= 233 | 11.11 (-88.9 to 700) |
| CD20+/27+Memory, Yr 2, Wk 48, n= 217 | -7.69 (-84.6 to 5616.7) |
| CD20+/27+Memory, Yr 3, Wk 24, n= 205 | -23.26 (-100 to 900) |
| CD20+/27+Memory, Yr 3, Wk 48, n= 196 | -35.29 (-97.1 to 3000) |
| CD20+/27+Memory, Yr 4, Wk 24, n= 191 | -40 (-92.6 to 1400) |
| CD20+/27+Memory, Yr 4, Wk 48, n= 175 | -50 (-92.3 to 3166.7) |
| CD20+/27+Memory, Yr 5, Wk 24, n= 166 | -50 (-97.7 to 500) |
| CD20+/27+Memory, Yr 5, Wk 48, n= 160 | -58.87 (-96 to 800) |
| CD20+/27+Memory, Yr 6, Wk 24, n= 153 | -57.89 (-96.2 to 533.3) |
| CD20+/27+Memory, Yr 6, Wk 48, n= 108 | -63.4 (-92.9 to 400) |
| CD20+/27+Memory, Yr 7, Wk 24, n= 106 | -67.18 (-96.2 to 500) |
| CD20+/27+Memory, Yr 7, Wk 48, n= 81 | -71.43 (-92.3 to 400) |
| CD20+/27+Memory, Yr 8, Wk 24, n= 52 | -67.03 (-96 to 200) |
| CD20+/27+Memory, Yr 8, Wk 48, n= 27 | -64.71 (-88.8 to 600) |
| CD20+/27+Memory, Yr 9, Wk 24, n= 2 | -75.96 (-76.9 to -75) |
| CD20+/27+Memory, Exit, n= 202 | -61.41 (-100 to 1000) |
| CD20+/27-naive, Yr 1, Wk 24, n= 245 | -55.56 (-95.1 to 337.5) |
| CD20+/27-naive, Yr 1, Wk 48, n= 237 | -69.7 (-96.7 to 200) |
| CD20+/27-naive, Yr 2, Wk 24, n= 233 | -77.27 (-97.6 to 150) |
| CD20+/27-naive, Yr 2, Wk 48, n= 218 | -79.5 (-98.6 to 959) |
| CD20+/27-naive, Yr 3, Wk 24, n= 206 | -80.11 (-98.5 to 100) |
| CD20+/27-naive, Yr 3, Wk 48, n= 196 | -84.41 (-98.5 to 500) |
| CD20+/27-naive, Yr 4, Wk 24, n= 191 | -81.93 (-98.8 to 100) |
| CD20+/27-naive, Yr 4, Wk 48, n= 175 | -84.21 (-98.8 to 100) |
| CD20+/27-naive, Yr 5, Wk 24, n= 166 | -86.09 (-100 to 66.7) |
| CD20+/27-naive, Yr 5, Wk 48, n= 161 | -87.5 (-99.2 to 57.7) |
| CD20+/27-naive, Yr 6, Wk 24, n= 154 | -86.88 (-100 to 233.3) |
| CD20+/27-naive, Yr 6, Wk 48, n= 109 | -86.93 (-97.7 to 100) |
| CD20+/27-naive, Yr 7, Wk 24, n= 107 | -87.39 (-98.4 to 300) |
| CD20+/27-naive, Yr 7, Wk 48, n= 82 | -84.78 (-98 to 300) |
| CD20+/27-naive, Yr 8, Wk 24, n= 52 | -83.7 (-97.9 to 510) |
| CD20+/27-naive, Yr 8, Wk 48, n= 27 | -88.15 (-96.5 to 86.7) |
| CD20+/27-naive, Yr 9, Wk 24, n= 2 | -61.93 (-87.5 to -36.4) |
| CD20+/27-naive, Exit, n= 203 | -86.42 (-99 to 433.3) |
| CD20+/69+activated, Yr 1, Wk 24, n= 240 | -33.35 (-98.5 to 3000) |
| CD20+/69+activated, Yr 1, Wk 48, n= 238 | -56.33 (-99.7 to 1331.6) |
| CD20+/69+activated, Yr 2, Wk 24, n= 236 | -65.21 (-100 to 580) |
| CD20+/69+activated, Yr 2, Wk 48, n= 223 | -72.31 (-100 to 502.9) |
| CD20+/69+activated, Yr 3, Wk 24, n= 208 | -83.71 (-100 to 306.9) |
| CD20+/69+activated, Yr 3, Wk 48, n= 202 | -89.28 (-100 to 325.7) |
| CD20+/69+activated, Yr 4, Wk 24, n= 201 | -93.14 (-100 to 89.3) |
| CD20+/69+activated, Yr 4, Wk 48, n= 185 | -94.85 (-100 to 263.6) |
| CD20+/69+activated, Yr 5, Wk 24, n= 180 | -96.99 (-100 to 13.4) |
| CD20+/69+activated, Yr 5, Wk 48, n= 172 | -98.04 (-100 to 14.3) |
| CD20+/69+activated, Yr 6, Wk 24, n= 165 | -98.04 (-100 to -16.7) |
| CD20+/69+activated, Yr 6, Wk 48, n= 125 | -98.76 (-100 to 20) |
| CD20+/69+activated, Yr 7, Wk 24, n= 116 | -98.85 (-100 to -24.1) |
| CD20+/69+activated, Yr 7, Wk 48, n=89 | -99.22 (-100 to -76) |
| CD20+/69+activated, Yr 8, Wk 24, n= 56 | -99.33 (-100 to -83.7) |
| CD20+/69+activated, Yr 8, Wk 48, n= 28 | -99.71 (-100 to -95.8) |
| CD20+/69+activated, Yr 9, Wk 24, n= 2 | -97.92 (-100 to -95.8) |
| CD20+/69+activated, Exit, n= 226 | -98.99 (-100 to 453.1) |
| CD20-/138+plasma cells, Yr 1, Wk 24, n= 244 | -37.2 (-100 to 3400) |
| CD20-/138+plasma cells, Yr 1, Wk 48, n= 241 | -50 (-100 to 4700) |
| CD20-/138+plasma cells, Yr 2, Wk 24, n= 240 | -47.83 (-100 to 1200) |
| CD20-/138+plasma cells, Yr 2, Wk 48, n= 226 | -53.92 (-100 to 5500) |
| CD20-/138+plasma cells, Yr 3, Wk 24, n= 212 | -64.82 (-100 to 1000) |
| CD20-/138+plasma cells, Yr 3, Wk 48, n= 205 | -71.43 (-100 to 2566.7) |
| CD20-/138+plasma cells, Yr 4, Wk 24, n= 205 | -73.76 (-100 to 910) |
| CD20-/138+plasma cells, Yr 4, Wk 48, n= 187 | -81.58 (-100 to 586.4) |
| CD20-/138+plasma cells, Yr 5, Wk 24, n= 182 | -86.46 (-100 to 133.3) |
| CD20-/138+plasma cells, Yr 5, Wk 48, n= 175 | -88.89 (-100 to 300) |
| CD20-/138+plasma cells, Yr 6, Wk 24, n= 168 | -91.3 (-100 to 900) |
| CD20-/138+plasma cells, Yr 6, Wk 48, n= 127 | -90.91 (-100 to 2100) |
| CD20-/138+plasma cells, Yr 7, Wk 24, n= 118 | -92.31 (-100 to 1700) |
| CD20-/138+plasma cells, Yr 7, Wk 48, n= 92 | -93.83 (-100 to 200) |
| CD20-/138+plasma cells, Yr 8, Wk 24, n= 57 | -93.39 (-100 to -11.1) |
| CD20-/138+plasma cells, Yr 8, Wk 48, n= 28 | -97.56 (-100 to -75) |
| CD20-/138+plasma cells, Yr 9, Wk 24, n= 2 | -80.78 (-90.1 to -71.4) |
| CD20-/138+plasma cells, Exit, n= 226 | -88.58 (-100 to 1600) |
| Total CD19+ B-cells (CD19+), Yr 1, Wk 24, n= 250 | -32.56 (-91.7 to 400) |
| Total CD19+ B-cells (CD19+), Yr 1, Wk 48, n= 251 | -51.61 (-94.6 to 214.3) |
| Total CD19+ B-cells (CD19+), Yr 2, Wk 24, n= 244 | -61.71 (-95.5 to 244.4) |
| Total CD19+ B-cells (CD19+), Yr 2, Wk 48, n= 231 | -66.67 (-96 to 1576.3) |
| Total CD19+ B-cells (CD19+), Yr 3, Wk 24, n= 217 | -70.21 (-96.3 to 153.3) |
| Total CD19+ B-cells (CD19+), Yr 3, Wk 48, n= 209 | -74.24 (-97.3 to 276.5) |
| Total CD19+ B-cells (CD19+), Yr 4, Wk 24, n= 209 | -75.61 (-97.8 to 82.4) |
| Total CD19+ B-cells (CD19+), Yr 4, Wk 48, n= 192 | -78.54 (-97.8 to 528.2) |
| Total CD19+ B-cells (CD19+), Yr 5, Wk 24, n= 187 | -80.56 (-97.8 to 141.2) |
| Total CD19+ B-cells (CD19+), Yr 5, Wk 48, n= 179 | -81.14 (-98.1 to 100) |
| Total CD19+ B-cells (CD19+), Yr 6, Wk 24, n= 172 | -81.85 (-98.1 to 75) |
| Total CD19+ B-cells (CD19+), Yr 6, Wk 48, n= 130 | -82.34 (-98.5 to 79.5) |
| Total CD19+ B-cells (CD19+), Yr 7, Wk 24, n= 120 | -82.73 (-97.6 to 125) |
| Total CD19+ B-cells (CD19+), Yr 7, Wk 48, n= 95 | -80.95 (-97.8 to 172.2) |
| Total CD19+ B-cells (CD19+), Yr 8, Wk 24, n= 59 | -79.87 (-96.9 to 250) |
| Total CD19+ B-cells (CD19+), Yr 8, Wk 48, n= 28 | -84.79 (-95.6 to 94.4) |
| Total CD19+ B-cells (CD19+), Yr 9, Wk 24, n= 2 | -66.04 (-85.4 to -46.7) |
| Total CD19+ B-cells (CD19+), Exit, n= 232 | -80.81 (-98.2 to 178.6) |
Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change \>0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).
| Percentage of Participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 48, n=263 | 5.7 |
| Year 2, Week 48, n=256 | 12.1 |
| Year 3, Week 48, n=239 | 18 |
| Year 4, Week 48, n=212 | 20.8 |
| Year 5, Week 48, n=195 | 22.6 |
| Year 6, Week 48, n=187 | 25.1 |
| Year 7, Week 48, n=126 | 30.2 |
| Year 8, Week 48, n=65 | 29.2 |
The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).
| Score on a scale | Belimumab 10 mg/kg IV |
|---|---|
| MCS, Year 1, Week 48, n= 259 | 2.47 ± 10.113 |
| MCS, Year 2, Week 48, n= 255 | 2.99 ± 10.428 |
| MCS, Year 3, Week 48, n= 236 | 2.54 ± 10.399 |
| MCS, Year 4, Week 48, n= 212 | 2.52 ± 11.099 |
| MCS, Year 5, Week 48, n= 193 | 2.22 ± 11.22 |
| MCS, Year 6, Week 48, n= 185 | 2.71 ± 11.274 |
| MCS, Year 7, Week 48, n= 126 | 3.19 ± 11.269 |
| MCS, Year 8, Week 48, n= 65 | 3.91 ± 11.066 |
| PCS, Year 1, Week 48, n= 259 | 3.41 ± 8.603 |
| PCS, Year 2, Week 48, n= 255 | 4.64 ± 8.3 |
| PCS, Year 3, Week 48, n= 236 | 5.93 ± 8.51 |
| PCS, Year 4, Week 48, n= 212 | 5.01 ± 8.752 |
| PCS, Year 5, Week 48, n= 193 | 6.12 ± 9.314 |
| PCS, Year 6, Week 48, n= 185 | 4.79 ± 9.406 |
| PCS, Year 7, Week 48, n= 126 | 7.7 ± 9.887 |
| PCS, Year 8, Week 48, n= 65 | 6.73 ± 10.107 |
The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).
| Score on a scale | Belimumab 10 mg/kg IV |
|---|---|
| Bodily pain, Year 1 , Week 48, n= 261 | 9.7 ± 23.36 |
| Bodily pain, Year 2 , Week 48, n= 255 | 9.2 ± 24.389 |
| Bodily pain, Year 3 , Week 48, n= 236 | 10.97 ± 23.409 |
| Bodily pain, Year 4 , Week 48, n= 212 | 8.33 ± 24.181 |
| Bodily pain, Year 5 , Week 48, n= 193 | 10.88 ± 24.549 |
| Bodily pain, Year 6 , Week 48, n= 185 | 8.82 ± 23.636 |
| Bodily pain, Year 7 , Week 48, n= 126 | 14.48 ± 24.969 |
| Bodily pain, Year 8 , Week 48, n= 65 | 11.94 ± 22.93 |
| General health, Year 1 , Week 48, n= 260 | 5.66 ± 14.693 |
| General health, Year 2 , Week 48, n= 255 | 6.14 ± 15.156 |
| General health, Year 3 , Week 48, n= 236 | 8.84 ± 15.929 |
| General health, Year 4 , Week 48, n= 212 | 7.29 ± 16.069 |
| General health, Year 5 , Week 48, n= 193 | 9.19 ± 17.742 |
| General health, Year 6 , Week 48, n= 185 | 7.24 ± 18.187 |
| General health, Year 7 , Week 48, n= 126 | 8.71 ± 18.693 |
| General health, Year 8 , Week 48, n= 65 | 8.18 ± 19.994 |
| Mental health, Year 1 , Week 48, n= 260 | 4 ± 17.71 |
| Mental health, Year 2 , Week 48, n= 255 | 3.62 ± 17.46 |
| Mental health, Year 3 , Week 48, n= 236 | 2.34 ± 17.817 |
| Mental health, Year 4 , Week 48, n= 212 | 2.33 ± 20.172 |
| Mental health, Year 5 , Week 48, n= 193 | 1.78 ± 20.662 |
| Mental health, Year 6 , Week 48, n= 185 | 3.6 ± 19.968 |
| Mental health, Year 7 , Week 48, n= 126 | 4.39 ± 19.811 |
| Mental health, Year 8 , Week 48, n= 65 | 6.08 ± 18.551 |
| Physical functioning, Year 1 , Week 48, n= 260 | 6.34 ± 21.498 |
| Physical functioning, Year 2 , Week 48, n= 255 | 6.25 ± 21.185 |
| Physical functioning, Year 3 , Week 48, n= 236 | 7.85 ± 21.994 |
| Physical functioning, Year 4 , Week 48, n= 212 | 6.38 ± 22.112 |
| Physical functioning, Year 5 , Week 48, n= 193 | 7.62 ± 24.486 |
| Physical functioning, Year 6 , Week 48, n= 185 | 6.72 ± 24.81 |
| Physical functioning, Year 7 , Week 48, n= 126 | 11.25 ± 26.422 |
| Physical functioning, Year 8 , Week 48, n= 65 | 11.83 ± 27.065 |
| Role emotional, Year 1 , Week 48, n= 261 | 4.96 ± 25.714 |
| Role emotional, Year 2 , Week 48, n= 254 | 4.74 ± 27.92 |
| Role emotional, Year 3 , Week 48, n= 236 | 3.73 ± 28.258 |
| Role emotional, Year 4 , Week 48, n= 212 | 3.32 ± 28.237 |
| Role emotional, Year 5 , Week 48, n= 193 | 3.61 ± 28.774 |
| Role emotional, Year 6 , Week 48, n= 185 | 3.13 ± 31.614 |
| Role emotional, Year 7 , Week 48, n= 126 | 3.27 ± 30.385 |
| Role emotional, Year 8 , Week 48, n=65 | 7.18 ± 33.91 |
| Role physical, Year 1 , Week 48, n= 260 | 8.91 ± 26.393 |
| Role physical, Year 2 , Week 48, n= 253 | 8 ± 27.106 |
| Role physical, Year 3 , Week 48, n= 236 | 10.05 ± 26.525 |
| Role physical, Year 4 , Week 48, n= 212 | 8.27 ± 28.998 |
| Role physical, Year 5 , Week 48, n= 193 | 10.86 ± 29.839 |
| Role physical, Year 6 , Week 48, n= 185 | 6.91 ± 30.995 |
| Role physical, Year 7 , Week 48, n= 126 | 13.53 ± 31.347 |
| Role physical, Year 8 , Week 48, n= 65 | 11.51 ± 34.385 |
| Social functioning, Year 1 , Week 48, n= 261 | 7.61 ± 26.901 |
| Social functioning, Year 2 , Week 48, n= 255 | 7.21 ± 27.218 |
| Social functioning, Year 3 , Week 48, n= 236 | 9.59 ± 27.989 |
| Social functioning, Year 4 , Week 48, n= 212 | 6.9 ± 28.598 |
| Social functioning, Year 5 , Week 48, n= 193 | 8.16 ± 30.079 |
| Social functioning, Year 6 , Week 48, n= 185 | 6.96 ± 28.695 |
| Social functioning, Year 7 , Week 48, n= 126 | 10.32 ± 31.784 |
| Social functioning, Year 8 , Week 48, n= 65 | 9.81 ± 32.135 |
| Vitality, Year 1 , Week 48, n= 260 | 8.87 ± 21.449 |
| Vitality, Year 2 , Week 48, n= 255 | 7.13 ± 22.287 |
| Vitality, Year 3 , Week 48, n= 236 | 8.17 ± 20.742 |
| Vitality, Year 4 , Week 48, n= 212 | 8.04 ± 21.742 |
| Vitality, Year 5 , Week 48, n= 193 | 8.23 ± 24.937 |
| Vitality, Year 6 , Week 48, n= 185 | 6.93 ± 23.023 |
| Vitality, Year 7 , Week 48, n= 126 | 11.69 ± 22.709 |
| Vitality, Year 8 , Week 48, n= 65 | 6.47 ± 22.033 |
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).
| Score on a scale | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 48, n= 260 | 4.91 ± 10.785 |
| Year 2, Week 48, n= 252 | 4.82 ± 11.414 |
| Year 3, Week 48, n= 235 | 4.85 ± 11.614 |
| Year 4, Week 48, n= 210 | 4.14 ± 11.269 |
| Year 5, Week 48, n= 193 | 4.81 ± 11.962 |
| Year 6, Week 48, n= 184 | 3.7 ± 11.787 |
| Year 7, Week 48, n= 126 | 5.74 ± 11.644 |
| Year 8, Week 48, n= 65 | 4.28 ± 10.949 |
The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (\>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).
| Percentage of Participants | Belimumab 10 mg/kg IV |
|---|---|
| Year 1, Week 48 | 50.4 |
| Year 2, Week 48 | 45.9 |
| Year 3, Week 48 | 44.4 |
| Year 4, Week 48 | 36.2 |
| Year 5, Week 48 | 40.3 |
| Year 6, Week 48 | 33.2 |
| Year 7, Week 48 | 26.1 |
| Year 8, Week 48 | 13.1 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 until follow-up (up to Week 440).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10 mg/kg IV | — | 112/268 (41.8%) | 266/268 (99.3%) |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| Any eventInfections and infestations | 44/268 |
| Any eventMusculoskeletal and connective tissue disorders | 22/268 |
| Any eventGeneral disorders | 20/268 |
| Any eventGastrointestinal disorders | 19/268 |
| Any eventInjury, poisoning and procedural complications | 15/268 |
| Any eventNervous system disorders | 15/268 |
| Any eventNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/268 |
| Non-cardiac chest painGeneral disorders | 12/268 |
| Any eventRespiratory, thoracic and mediastinal disorders | 11/268 |
| Any eventVascular disorders | 10/268 |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| Any eventInfections and infestations | 243/268 |
| Any eventMusculoskeletal and connective tissue disorders | 217/268 |
| Any eventGastrointestinal disorders | 191/268 |
| Any eventSkin and subcutaneous tissue disorders | 163/268 |
| Any eventNervous system disorders | 162/268 |
| Any eventInjury, poisoning and procedural complications | 155/268 |
| Any eventRespiratory, thoracic and mediastinal disorders | 154/268 |
| Any eventGeneral disorders | 151/268 |
| Any eventPsychiatric disorders | 107/268 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 106/268 |
| Age, Continuous(Years) | Belimumab 10 mg/kg IV |
|---|---|
| Mean | 42.8 ± 11.33 |
| Sex: Female, Male(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| Female | 250 |
| Male | 18 |
| Race/Ethnicity, Customized(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| Black or African American/African Heritage | 57 |
| American Indian or Alaska Native | 8 |
| Asian: Central Asian Heritage | 0 |
| Asian: East Asian Heritage | 2 |
| Asian: Japanese Heritage | 3 |
| Asian: South Asian Heritage | 1 |
| Asian: Southeast Asian Heritage | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White: Middle East/North African Heritage | 3 |
| White: White/Caucasian/European Heritage | 183 |
| Mixed Race | 4 |
The record gives a start of Aug 2008, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →